CPC

COOPERATIVE PATENT CLASSIFICATION

C

CHEMISTRY; METALLURGY
(NOTES omitted)

CHEMISTRY

C12

BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMEOLOGY; MUTATION OR GENETIC ENGINEERING
(NOTES omitted)

C12N

MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing microorganisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from microorganisms or animal material A01N 63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS (preservation of living parts of humans or animals A01N 1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q)

NOTES

1. Documents relating to the use of vectors or hosts for the preparation of specific peptides, e.g. enzymes, are classified in subclass C07K or in group C12N 9/00 according to the peptides, with the appropriate indexing codes.
2. Attention is drawn to Notes (1) to (3) following the title of Class C12.
3. When classifying in this group, classification is also made in group B01D 15/08 insofar as subject matter of general interest relating to chromatography is concerned.

WARNINGS

1. The following IPC groups are not in the CPC scheme. The subject matter for these IPC groups is classified in the following CPC groups:
   - C12N 1/11 covered by C12N 1/15
   - C12N 1/13 covered by C12N 1/15
   - C12N 1/15 covered by C12N 1/15
   - C12N 1/19 covered by C12N 1/15
   - C12N 1/21 covered by C12N 1/15
   - C12N 5/02 covered by C12N 5/00, C12N 5/04 - C12N 5/166
   - C12N 5/07 - C12N 5/095 covered by C12N 5/06 and subgroups
   - C12N 5/18 - C12N 5/28 covered by C12N 5/16 and subgroups
   - C12N 5/18 covered by C12N 5/16
   - C12N 5/20 covered by C12N 5/163
   - C12N 5/22 covered by C12N 5/16
   - C12N 5/24 covered by C12N 5/16
   - C12N 5/26 covered by C12N 5/166
   - C12N 5/28 covered by C12N 5/166
   - C12N 7/01 covered by C12N 7/00
   - C12N 9/02-C12N 9/08 covered by C12N 9/2408
   - C12N 9/26 covered by C12N 9/2408
   - C12N 9/28-C12N 9/30 covered by C12N 9/2408
   - C12N 9/32 covered by C12N 9/2408
   - C12N 9/34 covered by C12N 9/2408
   - C12N 9/36 covered by C12N 9/2408
   - C12N 9/38 covered by C12N 9/2408
   - C12N 9/40 covered by C12N 9/2408
   - C12N 9/42 covered by C12N 9/2408
   - C12N 9/44 covered by C12N 9/2408
   - C12N 9/46 covered by C12N 9/2408
   - C12N 9/56 covered by C12N 9/2408
   - C12N 9/66 covered by C12N 9/2408
   - C12N 9/68 covered by C12N 9/2408
2. In this subclass non-limiting references (in the sense of paragraph 39 of the Guide to the IPC) may still be displayed in the scheme.
NOTE

In this group, the following words are used with the meanings indicated:

- a "multipotent" cell is restricted to one lineage;
- "progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. Unless provided for otherwise, committed progenitors are classified with their progeny.

WARNING

This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to CPC C12N 5/0037 - C12N 5/0056

NOTE

In this group, the following words are used with the meanings indicated:

- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);

Invertebrate cells or tissues; e.g. insect cells; Culture media therefor
NOTE

Three-dimensional culture, tissue culture or organ culture are classified with the corresponding cells, if not specially provided for

5/0603 . . . [Embryonic cells (production of embryos, nuclear transfer A01K 67/027); Embryoid bodies]

5/0604 . . . [Whole embryos; Culture medium therefor]

5/0605 . . . [Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly]

5/0606 . . . [Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N 5/0611), induced pluripotent stem cells C12N 5/0696]

5/0607 . . . [Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N 5/0696)]

5/0608 . . . [Germ cells (production of embryos, nuclear transfer A01K 67/027); Not used, see subgroups]

5/0609 . . . [Oocytes, oogonia (fertilised oocytes C12N 5/0604)]

5/061 . . . [Sperm cells, spermatogonia]

5/0611 . . . [Primordial germ cells, e.g. embryonic germ cells [EGI]]

5/0612 . . . [sorting of gametes, e.g. according to sex or motility]

5/0613 . . . [Cells from endocrine organs (pancreas C12N 5/0676, gonads C12N 5/0681)]

5/0614 . . . [Adrenal gland]

5/0615 . . . [Pineal gland]

5/0616 . . . [Pituitary gland]

5/0617 . . . [Thyroid and parathyroid glands]

5/0618 . . . [Cells of the nervous system]

5/0619 . . . [Neurons]

5/062 . . . [Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain]

5/0621 . . . [Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N 5/062)]

5/0622 . . . [Gial cells, e.g. astrocytes, oligodendrocytes; Schwann cells]

5/0623 . . . [Stem cells]

5/0625 . . . [Epidermal cells, skin cells; Cells of the oral mucosa]

5/0626 . . . [Melanocytes]

5/0627 . . . [Hair cells]

5/0628 . . . [Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles C12N 5/0666)]

5/0629 . . . [Keratinocytes; Whole skin]

5/063 . . . [Keratinocyte stem cells; Keratinocyte progenitors]

5/0631 . . . [Mammary cells]

5/0632 . . . [Cells of the oral mucosa]

5/0633 . . . [Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands]

5/0634 . . . [Cells from the blood or the immune system]

NOTE

Committed progenitors are classified with their progeny

5/0635 . . . [B lymphocytes]

5/0636 . . . [T lymphocytes]

5/0637 . . . [Immunosuppressive T lymphocytes, e.g. regulatory T cells (Treg)]

5/0638 . . . [Cytotoxic T lymphocytes (CTL), lymphokine activated killer cells [LAK]]

5/0639 . . . [Dendritic cells, e.g. Langherhans cells in the epidermis]

5/064 . . . [Immunosuppressive dendritic cells]

5/0641 . . . [Erythrocytes]

5/0642 . . . [Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells]

5/0643 . . . [Osteoclasts]

5/0644 . . . [Platelets; Megakaryocytes]

5/0645 . . . [Macrophages, e.g. Kueper cells in the liver; Monocytes]

5/0646 . . . [Natural killers cells [NK], NKT cells]

5/0647 . . . [Haematopoietic stem cells; Uncommitted or multipotent progenitors]

5/0648 . . . [Splenocytes]

5/065 . . . [Thymocytes]

5/0651 . . . [Lymph nodes]

5/0652 . . . [Cells of skeletal and connective tissues; Mesenchyme]

5/0653 . . . [Adipocytes; Adipose tissue]

5/0654 . . . [Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth]

5/0655 . . . [Chondrocytes; Cartilage]

5/0656 . . . [Adult fibroblasts]

5/0657 . . . [Cardiomycocytes; Heart cells]

5/0658 . . . [Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts]

5/0659 . . . [Satellite cells]

5/066 . . . [Tenocytes; Tendons, Ligaments]

5/0661 . . . [Smooth muscle cells]

5/0662 . . . [Stem cells]

5/0663 . . . [Bone marrow mesenchymal stem cells (BM-MSC)]

5/0664 . . . [Dental pulp stem cells, Dental follicle stem cells]

5/0665 . . . [Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood]

5/0666 . . . [Mesenchymal stem cells from hair follicles]

5/0667 . . . [Adipose-derived stem cells [ADSC]; Adipose stromal stem cells]

5/0668 . . . [Mesenchymal stem cells from other natural sources]

5/0669 . . . [Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N 5/0647, C12N 5/0663)]

5/067 . . . [Hepatocytes]

5/0671 . . . [Three-dimensional culture, tissue culture or organ culture; Encapsulated cells]

5/0672 . . . [Stem cells; Progenitor cells; Precursor cells; Oval cells]

5/0676 . . . [Pancreatic cells]
5/0677 . . . . [Three-dimensional culture, tissue culture or organ culture; Encapsulated cells]
5/0678 . . . . [Stem cells; Progenitor cells; Precursor cells]
5/0679 . . . . [Cells of the gastro-intestinal tract]
5/068 . . . . [Stem cells; Progenitors]
5/0681 . . . . [Cells of the genital tract; Non-germinal cells from gonads; Not used, see subgroups]
5/0682 . . . . [Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N 5/0609)]
5/0683 . . . . [Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia C12N 5/0661)]
5/0684 . . . . [Cells of the urinary tract or kidneys]
5/0685 . . . . [Bladder epithelial cells]
5/0686 . . . . [Kidney cells]
5/0687 . . . . [Renal stem cells; Renal progenitors]
5/0688 . . . . [Cells from the lungs or the respiratory tract]
5/0689 . . . . [Stem cells; Progenitors]
5/069 . . . . [Vascular Endothelial cells]
5/0691 . . . . [Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels]
5/0692 . . . . [Stem cells; Progenitor cells; Precursor cells]
5/0693 . . . . [Tumour cells; Cancer cells]
5/0694 . . . . [Cells of blood, e.g. leukemia cells, myeloma cells]
5/0695 . . . . [Stem cells; Progenitor cells; Precursor cells]
5/0696 . . . . [Artificially induced pluripotent stem cells, e.g. iPS]
5/0697 . . . . [Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N 5/0691)]
5/0698 . . . . [Skin equivalents]
5/10 . . . . Cells modified by introduction of foreign genetic material [Not used, see subgroups]
5/12 . . . . Fused cells, e.g. hybridomas
5/14 . . . . Plant cells
5/16 . . . . Animal cells
5/163 . . . . [one of the fusion partners being a B or a T lymphocyte]
5/166 . . . . [resulting from interspecies fusion]

7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K 39/00)

WARNING

From March 15, 2012 groups C12N 7/02 - C12N 7/08 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N 2710/00-C12N 2795/00.

7/02 . . . . Recovery or purification
7/025 . . . . [Packaging cell lines, e.g. transcomplementing cell lines, for production of virus]
7/04 . . . . Inactivation or attenuation; Producing viral sub-units

7/045 . . . . [Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered]
7/06 . . . . [Inactivation or attenuation] by chemical treatment
7/08 . . . . [Inactivation or attenuation] by serial passage of virus

9/00 Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K 8/66, A61Q 11/00; medicinal preparations containing enzymes or proenzymes A61K 38/43; enzyme containing detergent compositions C11D; enzymes with nucleic acid structure, e.g. ribozymes, C12N 15/113); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C 1/00)

NOTE

Enzymes are generally categorized below according to the “Nomenclature and Classification of Enzymes” of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis.

9/0002 . . . . (Antibodies with enzymatic activity, e.g. abzymes)
9/0004 . . . . [Oxidoreductases (1.1)]
9/0006 . . . . (acting on CH-OH groups as donors (1.1))
9/0008 . . . . (acting on the aldehyde or oxo group of donors (1.2))
9/001 . . . . (acting on the CH-CH group of donors (1.3))
9/0012 . . . . (acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7))
9/0014 . . . . (acting on the NH₂ group of donors (1.4))
9/0016 . . . . (with NAD or NADP as acceptor (1.4.1))
9/0018 . . . . (Phenylalanine dehydrogenase (1.4.1.20))
9/002 . . . . (with a cytochrome as acceptor (1.4.2))
9/0022 . . . . (with oxygen as acceptor (1.4.3))
9/0024 . . . . (D-Amino acid oxidase (1.4.3.3))
9/0026 . . . . (on CH-NH groups of donors (1.5))
9/0028 . . . . (with NAD or NADP as acceptor (1.5.1))
9/003 . . . . (Dihydrofolate reductase [DHFR] (1.5.1.3))
9/0032 . . . . (with oxygen as acceptor (1.5.3))
9/0034 . . . . (Sarcosine oxidase (1.5.3.1))
9/0036 . . . . (acting on NADH or NADPH (1.6))
9/0038 . . . . (with a heme protein as acceptor (1.6.2))
9/004 . . . . (Cytochrome-b₅ reductase (1.6.2.2))
9/0042 . . . . (NADPH-cytochrome P₄₅₀ reductase (1.6.2.4))
9/0044 . . . . (acting on other nitrogen compounds as donors (1.7))
9/0046 . . . . (with oxygen as acceptor (1.7.3))
9/0048 . . . . (Uricase (1.7.3.3))
9/0051 . . . . (acting on a sulfur group of donors (1.8))
9/0053 . . . . (acting on a heme group of donors (1.9))
9/0055 . . . . (acting on diphenols and related substances as donors (1.10))
9/0057 . . . . (with oxygen as acceptor (1.10.3))
9/0059 . . . . (Catechol oxidase (1.10.3.1), i.e. tyrosinase)
9/0061 . . . . (Laccase (1.10.3.2))
9/0063 . . . . (Ascorbate oxidase (1.10.3.3))
9/0065 . . . . (acting on hydrogen peroxide as acceptor (1.11))
9/0067 . . . . (acting on hydrogen as donor (1.12))
transferring phosphorus containing groups, e.g. 
{ transferring nitrogenous groups (2.6) }
{ transferring alkyl or aryl groups other than 
Acyltransferases (2.3) }
{ transferring aldehyde or ketonic groups (2.2) }
{ transferring one-carbon groups (2.1) }
{ acting on reduced flavodoxin as donor (1.19) }
{ acting on iron-sulfur proteins as donor (1.18) }
{ acting on CH or CH$_2$ groups (1.17) }
{ with NADH or NADPH as one donor, and 
incorporation of one atom of oxygen 1.14.13 }
{ with a reduced iron-sulfur protein as one 
donor (1.14.15) }
{ on single donors with incorporation of 
one atom of oxygen 1.14.13 }
{ transferring other glycosyl groups (2.4.99) }
{ Pentosyltransferases (2.4.2) }
{ transferring glycosyl groups other than 
methyl groups (2.5) }
{ transferring alkyl or aryl groups other than methyl groups (2.5) }
{ transferring groups other than amino-acyl 
groups (3.17) }
{ transferring one-carbon groups (2.1) }
{ Methyltransferases (general) (2.1.1.1) }
{ Catechol O-methyltransferase (2.1.16) }
{ Hydroxymethyl- formyltransferases (2.1.2.1) }
{ Carboxy- and carbamoyltransferases (2.1.3) }
{ transferring aldehyde or ketonic groups (2.2) }
{ Acyltransferases (2.3) }
{ transferring groups other than amino-acyl 
groups (2.3.1) }
{ Chloramphenicol O-acetyltransferase (2.3.1.28) }
{ Naringenin-chalcone synthase (2.3.1.74), 
i.e. chalcone synthase }
{ Aminocyclotransferases (2.3.2) }
{ Protein-glutamine gamma- 
glutamyltransferase (2.3.2.13, i.e. 
transglutaminase or factor XIII) }
{ Glycosyltransferases (2.4) }
{ Hexosyltransferases (2.4.1) }
{ Levensucrase (2.4.1.10) }
{ Cellulose synthases (2.4.1.12; 2.4.1.29) }
{ Sucrose synthase (2.4.1.13) }
{ Sucrose phosphate synthase (2.4.1.14) }
{ 1,4-Alpha-glucan branching enzyme 
(2.4.1.18) }
{ Cyclomaltoolxtrin glucanotransferase 
(2.4.1.19) }
{ Pentoxytransferases (2.4.2) }
{ transferring other glycosyl groups (2.4.99) }
{ transferring alkyl or aryl groups other than 
methyl groups (2.5) }
{ Glutathione transferase (2.5.1.18) }
{ 3-Phosphoshikimate 1- 
carboxyvinyltransferase (2.5.1.19), i.e. 5- 
enolpyruvylshikimate-3-phosphate synthase }
{ transferring nitrogenous groups (2.6) }
{ transferring phosphorus containing groups, e.g. 
kinases (2.7) }
{ Phosphotransferases with an alcohol group as 
acceptor (2.7.1), e.g. protein kinases }
{ Thymidine kinase (2.7.1.21) }
{ Phosphotransferases with a carboxyl group as 
acceptor (2.7.2) }
{ Phosphotransferases with a nitrogenous group 
as acceptor (2.7.3) }
{ Phosphotransferases with a phosphate group 
as acceptor (2.7.4) }
{ Diphostrophotransferases (2.7.6) }
{ Nucleotidyltransferases (2.7.7) }
{ DNA-directed RNA polymerase (2.7.7.6) }
{ DNA-directed DNA polymerase (2.7.7.7), 
i.e. DNA replicase }
{ Polyribonucleotide nucleotidyltransferase 
(2.7.7.8), i.e. polynucleotide phosphorylase }
{ DNA nucleotidylxotransferase (2.7.7.31), 
i.e. terminal nucleotidyl transferase }
{ RNA-directed RNA polymerase (2.7.7.48), 
i.e. RNA replicase }
{ RNA-directed DNA polymerase (2.7.7.49), 
i.e. reverse transcriptase or telomerase }
{ RNA uridyltransferase (2.7.7.52) }
{ Transferases for other substituted phosphate 
groups (2.7.9) }
{ Transferases with paired acceptors (2.7.9) }
{ transferring sulfur containing groups (2.8) }
{ Hydrolyases (3) }
{ acting on ester bonds (3.1) }
{ Carboxylic ester hydrolases [(3.1)] }
{ Triglyceride splitting, e.g. by means of lipase 
and lipases }
{ Ribonucleases [RNAse, DNAse] (catalytic 
nuccleic acids C12N 15(113)] }
{ acting on glycosyl compounds (3.2) }
{ hydrolysing O- and S- glycosid compounds 
(3.2.1) }
{ Glucanases }
{ acting on alpha-1,4-glucosidic bonds }
{ Amylases }
{ Alpha-amyrase (3.2.1.1) }
{ (from microbiological source) }
{ Fungal source }
{ from plant source }
{ (Beta-amyrase (3.2.1.2)) }
{ Glucan 1,4-alpha-glucosidase 
(3.2.1.3), i.e. glucoamylase }
{ Betaxylofuranosidase (3.2.1.26), i.e. 
invertase }
{ acting on beta-1,4-glucosidic bonds }
{ Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 
3.2.1.150) }
{ Endo-1,3(4)-beta-glucanase (3.2.1.6) }
{ Chitinase (3.2.1.14) }
{ Beta-glucosidase (3.2.1.21) }
{ (Licheninase (3.2.1.73)) }
{ acting on alpha-1,6-glucosidic bonds }
{ Dextranase (3.2.1.11) }
{ Pullulanase (3.2.1.41) }
{ Isoamylase (3.2.1.68) }
{ acting on alpha-galactose-glycoside bonds, 
e.g. alpha-galactosidase (3.2.1.22) }
9/2468 . . . . [acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); betaagarase (3.2.1.81)]
9/2471 . . . . [Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase]
9/2474 . . . . [Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase]
9/2477 . . . . [Hemicellulases not provided in a preceding group]
9/248 . . . . . . [Xylanases]
9/2482 . . . . . . [Endo-1,4-beta-xylanase (3.2.1.8)]
9/2485 . . . . . . [Xylan endo-1,3-beta-xylanidase (3.2.1.32), i.e. endo-1,3-beta-xylanase]
9/2488 . . . . . . [Mannanases]
9/2491 . . . . . . [Beta-mannosidase (3.2.1.25), i.e. mannanase]
9/2494 . . . . . . [Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase]
9/2497 . . . . [hydrolysing N-glycosyl compounds (3.2.2)]
9/48 . . . . . . acting on peptide bonds (3.4)
9/485 . . . . . . [Exopeptidases (3.4.11-3.4.19)]
9/50 . . . . Proteinases , e.g. Endopeptidases (3.4.21-3.4.25]

**WARNING**

Group C12N 9/50 is impacted by reclassification into group C12N 9/52.

Groups C12N 9/50 and C12N 9/52 should be considered in order to perform a complete search.

9/503 . . . . {derived from viruses}
9/506 . . . . . . {derived from RNA viruses}
9/52 . . . . derived from bacteria [or Archaea]

**NOTE**

{In this group, Archaea, formerly known as Archaebacteria, are classified with bacteria.}

**WARNING**

Group C12N 9/52 is incomplete pending reclassification of documents from group C12N 9/50.

Groups C12N 9/50 and C12N 9/52 should be considered in order to perform a complete search.

9/54 . . . . . . bacteria being Bacillus
9/58 . . . . derived from fungi
9/60 . . . . . . from yeast
9/62 . . . . . . from Aspergillus
9/63 . . . . . . [derived from plants]
9/64 . . . . . . derived from animal tissue
9/6402 . . . . [from non-mammals]
9/6405 . . . . . . not being snakes
9/6408 . . . . . . [Serine endopeptidases (3.4.21)]
9/641 . . . . . . [Cysteine endopeptidases (3.4.22)]
9/6413 . . . . . . [Aspartic endopeptidases (3.4.23)]
9/6416 . . . . . . [Metalloendopeptidases (3.4.24)]
9/6418 . . . . . . [from snakes]
9/6421 . . . . . . [from mammals]
9/6424 . . . . . . [Serine endopeptidases (3.4.21)]
9/6427 . . . . . . [Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)]
9/6429 . . . . . . [Thrombin (3.4.21.5)]
9/6432 . . . . . . [Coagulation factor Xa (3.4.21.6)]
9/6435 . . . . . . [Plasmin (3.4.21.7), i.e. fibrinolysin]
9/6437 . . . . . . [Coagulation factor VIIa (3.4.21.21)]
9/644 . . . . . . [Coagulation factor IXa (3.4.21.22)]
9/6445 . . . . . . (Kallikreins (3.4.21.34; 3.4.21.35)]
9/6448 . . . . . . [Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)]
9/6451 . . . . . . [Coagulation factor XIa (3.4.21.38)]
9/6454 . . . . . . [(Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases]
9/6456 . . . . . . [Plasminogen activators]
9/6459 . . . . . . [(t-plasminogen activator (3.4.21.68), i.e. tPA]
9/6462 . . . . . . [(u-Plasminogen activator (3.4.21.73), i.e. urokinase]
9/6464 . . . . . . [Protein C (3.4.21.69)]
9/6467 . . . . . . [(Granzyymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)]
9/647 . . . . . . (Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups]
9/6472 . . . . . . [Cysteine endopeptidases (3.4.22)]
9/6475 . . . . . . [(Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)]
9/6478 . . . . . . [Aspartic endopeptidases (3.4.23)]
9/6481 . . . . . . [Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)]
9/6483 . . . . . . [Chymosin (3.4.23.4), i.e. rennin]
9/6486 . . . . . . [Renin (3.4.23.15)]
9/6489 . . . . . . [Metalloendopeptidases (3.4.24)]
9/6491 . . . . . . [(Matrix metalloproteases [MMP’s], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)]
9/6494 . . . . . . [(Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11)]
9/6497 . . . . . . [(Endothelin-converting enzyme (3.4.24.71)]
9/78 . . . . acting on carbon to nitrogen bonds other than peptide bonds (3.5)
9/80 . . . . acting on amide bonds in linear amides \{(3.5.1)\}
9/82 . . . . Asparaginase \{(3.5.1.1)\}
9/84 . . . . Penicillin amidase \{(3.5.1.11)\}
9/86 . . . . acting on amide bonds in cyclic amides, e.g. penicillinase \{(3.5.2)\}
9/88 . . . . Lysases (4.)
9/90 . . . . Isomerases (5.)
9/92 . . . . Glucose isomerase \{(5.3.1.5; 5.3.1.9; 5.3.1.18)\}
9/93 . . . . [(Ligases (6)\]
9/94 . . . . Pancreatin
9/96 . . . . Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

CPC - 2019.05
7
Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof

Enzymes or microbial cells being immobilised on or in an organic carrier

Enzymes or microbial cells being immobilised on or in an inorganic carrier

Cellulose or derivatives thereof

Enzymes or microbial cells being immobilised on or in a biological cell

Multi-enzyme systems

Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves

Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N 1/00, C12N 5/00, C12N 7/00); new plants per se A01H; plant reproduction by tissue culture techniques A01H 4/00; new animals per se A01K 67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K 48/00

Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor

Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {monoclonal antibodies C07K 16/00; apparatus for cell fusion C12M)

Bacteria

Fungi

Recombinant DNA-technology

Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H 21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P 19/34)

Note:
After the symbol C12N 15/10 - C12N 15/1096, and separated therefrom by a + sign, it is desirable to add the indexing codes selected from groups C12Q 2500/00 - C12Q 2565/634, relating to relevant technical features of the invention.
When more than one indexing code is selected, the different codes are separated by a + sign.
Example: C12N 15/1037 + C12Q 2537/125 + C12Q 2521/537

Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor.

[by means of a solid support carrier, e.g. particles, polymers]
[by chromatography, e.g. electrophoresis, ion-exchange, reverse phase]
[by using magnetic beads]
[by filtration, e.g. using filters, frits, membranes]
[Mutagenizing nucleic acids]
[By in vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair]
[by DNA shuffling, e.g. RSR, STEP, RPR]
[mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR]
[Isolating an individual clone by screening libraries]
[Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display]
[Ribosome/Polyosome display, e.g. SPERT, ARM]
[Preparation or screening of libraries displayed on scaffold proteins]
[SELEX]
[Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors]
[Protein x Protein interaction, e.g. two hybrid selection]
[Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms]
[mRNA-Display, e.g. polypeptide and encoding template are connected covalently]
[Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags]
[Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis]
[Differential gene expression library synthesis, e.g. subtracted libraries, differential screening]
[by coupling phenotype to genotype, not provided for in other groups of this subclass]
[Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays C12N 15/1086)]
[Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors]
[Preparation or screening of expression libraries, e.g. reporter assays]
[Design, preparation, screening or analysis of libraries using computer algorithms]
15/1093 . . . [General methods of preparing gene libraries, not provided for in other subgroups]

15/1096 . . . [cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR]

15/11 . . . DNA or RNA fragments; Modified forms thereof [DNA or RNA not used in recombinant technology, C07H 21/00]; [Non-coding nucleic acids having a biological activity]

**NOTE**

Documents relating to DNA or its corresponding RNA and their use in recombinant DNA technology or the preparation of specific peptides, e.g. enzymes, are classified in subclass C07K or in group C12N 9/00 according to the peptides, with the appropriate indexing codes relating to their use in recombinant technology. Groups C12N 15/11 - C12N 15/117 cover also the use of non-coding nucleic acids as active ingredients in medicinal preparations. The C12N 2303/00 ICO scheme has to be applied to these groups. When documents classifiable in one or more subgroups disclose general principles of the technology applicable to the whole field, classification is also made in group C12N 15/111.

15/111 . . . [General methods applicable to biologically active non-coding nucleic acids]

15/113 . . . Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex-forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N 15/8218)}

15/1131 . . . [against viruses]

15/1132 . . . [against retroviridae, e.g. HIV]

15/1133 . . . [against herpetoviridae, e.g. HSV]

15/1135 . . . [against oncogenes or tumor suppressor genes]

15/1136 . . . [against growth factors, growth regulators, cytokines, lymphokines or hormones]

15/1137 . . . [against enzymes (viral enzymes C12N 15/1131; receptors C12N 15/1138)]

15/1138 . . . [against receptors or cell surface proteins]

15/115 . . . Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {Nucleic acids binding to non-nucleic acids, e.g. aptamers}

**NOTE**

Aptamers fused to compounds which are already classified in groups C12N 15/11 - C12N 15/117, are classified with the corresponding compound.

15/117 . . . Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs

15/52 . . . Genes encoding for enzymes or proenzymes

**NOTE**

In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.

15/62 . . . DNA sequences coding for fusion proteins

**NOTE**

In this group, the following term is used with the meaning indicated:

- "fusion" means the fusion of two different proteins.

15/625 . . . [containing a sequence coding for a signal sequence]

15/63 . . . Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

15/635 . . . [Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracycline]

15/64 . . . General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

15/65 . . . using markers (enzymes used as markers C12N 15/52)

15/66 . . . General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

**NOTE**

In this group, the following expression is used with the meaning indicated:

- "non-functional linkers" means DNA sequences which are used to link DNA sequences and which have no known function of structural gene or regulating function.

15/67 . . . General methods for enhancing the expression

15/68 . . . Stabilisation of the vector

15/69 . . . Increasing the copy number of the vector

15/70 . . . Vectors or expression systems specially adapted for E. coli

**NOTES**

1. This group covers the use of E. coli as host.
2. Shuttle vectors also replicating in E. coli are classified according to the other host.

15/71 . . . Expression systems using regulatory sequences derived from the trp-operon

15/72 . . . Expression systems using regulatory sequences derived from the lac-operon

15/73 . . . Expression systems using phage (lambda) regulatory sequences

15/74 . . . Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

**NOTE**

This group covers the use of prokaryotes as hosts.
C12N

15/743 . . . . . . [for Agrobacterium; Rhizobium; Bradyrhizobium]
15/746 . . . . . . [for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)]
15/75 . . . . for Bacillus
15/76 . . . . . . for Actinomycetes; for Streptomycetes
15/77 . . . . . . for Corynebacterium; for Brevibacterium
15/78 . . . . . . for Pseudomonas
15/79 . . . . Vectors or expression systems specially adapted for eukaryotic hosts

NOTE
This group covers the use of eukaryotes as hosts.

15/80 . . . . . . for fungi
15/81 . . . . . . for yeasts
15/815 . . . . . . {for yeasts other than Saccharomyces}
15/82 . . . . . . for plant cells {, e.g. plant artificial chromosomes (PACs)}

WARNING
Documents are being continuously reclassified into this new classification scheme. See Warning notes below

15/8201 . . . . . . {Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation}
15/8202 . . . . . . {by biological means, e.g. cell mediated or natural vector}
15/8203 . . . . . . [Virus mediated transformation]
15/8205 . . . . . . [Agrobacterium mediated transformation]
15/8206 . . . . . . [by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated]
15/8207 . . . . . . [by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers]
15/8209 . . . . . . [Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers]

NOTE
Standard selectable markers such as neomycin phosphotransferase (NPT) are not systematically classified in C12N 15/8209

15/821 . . . . . . [Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers]
15/8212 . . . . . . [Colour markers, e.g. beta-glucoronidase [GUS], green fluorescent protein [GFP], carotenoid]
15/8213 . . . . . . [Targeted insertion of genes into the plant genome by homologous recombination]
15/8214 . . . . . . [Plastid transformation]

15/8216 . . . . . . {Methods for controlling, regulating or enhancing expression of transgenes in plant cells}
15/8217 . . . . . . [Gene switch]
15/8218 . . . . . . [Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]]
15/822 . . . . . . [Reducing position variability, e.g. by the use of scaffold attachment region/ matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression]
15/8221 . . . . . . [Transit peptides]
15/8222 . . . . . . [Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation]
15/8223 . . . . . . [Vegetative tissue-specific promoters]
15/8225 . . . . . . {Leaf-specific, e.g. including petioles, stomata}
15/8226 . . . . . . {Stem-specific, e.g. including tubers, beets}
15/8227 . . . . . . [Root-specific]
15/8229 . . . . . . [Meristem-specific, e.g. nodal, apical]
15/823 . . . . . . [Reproductive tissue-specific promoters]
15/8231 . . . . . . {Male-specific, e.g. anther, tapetum, pollen}
15/8233 . . . . . . {Female-specific, e.g. pistil, ovule}
15/8234 . . . . . . {Seed-specific, e.g. embryo, endosperm}
15/8235 . . . . . . [Fruit-specific]
15/8237 . . . . . . [Externally regulated expression systems]
15/8238 . . . . . . [chemically inducible, e.g. tetracycline]
15/8239 . . . . . . [pathogen inducible]
15/8241 . . . . . . {Phenotypically and genetically modified plants via recombinant DNA technology}
15/8242 . . . . . . [with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits]
15/8243 . . . . . . [involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine]
15/8245 . . . . . . [involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis]
15/8246 . . . . . . {Non-starch polysaccharides, e.g. cellulose, fructans, levans}
15/8247 . . . . . . [involving modified lipid metabolism, e.g. seed oil composition]
15/8249 . . . . . . [involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life]
<table>
<thead>
<tr>
<th>CPC Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>15/825</td>
<td>involving pigment biosynthesis</td>
</tr>
<tr>
<td></td>
<td><strong>NOTE</strong> Transgenic plants with altered flower morphology are also classified in this group</td>
</tr>
<tr>
<td>15/8251</td>
<td>Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis</td>
</tr>
<tr>
<td>15/8253</td>
<td>Methionine or cysteine</td>
</tr>
<tr>
<td>15/8254</td>
<td>Tryptophan or lysine</td>
</tr>
<tr>
<td>15/8255</td>
<td>involving lignin biosynthesis</td>
</tr>
<tr>
<td>15/8257</td>
<td>for the production of primary gene products, e.g. pharmaceutical products, interferon</td>
</tr>
<tr>
<td>15/8258</td>
<td>for the production of oral vaccines (antigens) or immunoglobulins</td>
</tr>
<tr>
<td>15/8259</td>
<td>Phytoremediation</td>
</tr>
<tr>
<td>15/8261</td>
<td>with agronomic (input) traits, e.g. crop yield</td>
</tr>
<tr>
<td>15/8262</td>
<td>involving plant development (not used)</td>
</tr>
<tr>
<td>15/8263</td>
<td>Ablation; Apoptosis</td>
</tr>
<tr>
<td>15/8265</td>
<td>Transgene containment, e.g. gene dispersal</td>
</tr>
<tr>
<td>15/8266</td>
<td>Abscission; Dehiscence; Senescence</td>
</tr>
<tr>
<td>15/8267</td>
<td>Seed dormancy, germination or sprouting</td>
</tr>
<tr>
<td>15/8269</td>
<td>Photosynthesis</td>
</tr>
<tr>
<td>15/827</td>
<td>Flower development or morphology, e.g. flowering promoting factor [FPF]</td>
</tr>
<tr>
<td>15/8271</td>
<td>for stress resistance, e.g. heavy metal resistance</td>
</tr>
<tr>
<td>15/8273</td>
<td>for drought, cold, salt resistance</td>
</tr>
<tr>
<td>15/8274</td>
<td>for herbicide resistance</td>
</tr>
<tr>
<td>15/8275</td>
<td>Glyphosate</td>
</tr>
<tr>
<td>15/8277</td>
<td>Phosphonotricin</td>
</tr>
<tr>
<td>15/8278</td>
<td>Sulfonylurea</td>
</tr>
<tr>
<td>15/8279</td>
<td>for biotic stress resistance, pathogen resistance, disease resistance</td>
</tr>
<tr>
<td>15/8281</td>
<td>for bacterial resistance</td>
</tr>
<tr>
<td>15/8282</td>
<td>for fungal resistance</td>
</tr>
<tr>
<td>15/8283</td>
<td>for virus resistance</td>
</tr>
<tr>
<td>15/8285</td>
<td>for nematode resistance</td>
</tr>
<tr>
<td>15/8286</td>
<td>for insect resistance</td>
</tr>
<tr>
<td>15/8287</td>
<td>for fertility modification, e.g. apomixis</td>
</tr>
<tr>
<td>15/8289</td>
<td>Male sterility</td>
</tr>
<tr>
<td>15/829</td>
<td>Female sterility</td>
</tr>
<tr>
<td>15/8291</td>
<td>Hormone-influenced development</td>
</tr>
<tr>
<td>15/8293</td>
<td>Abscisic acid [ABA]</td>
</tr>
<tr>
<td>15/8294</td>
<td>Auxins</td>
</tr>
<tr>
<td>15/8295</td>
<td>Cytokinins</td>
</tr>
<tr>
<td>15/8297</td>
<td>Gibberellins; GA3</td>
</tr>
<tr>
<td>15/8298</td>
<td>Brassinosteroids</td>
</tr>
<tr>
<td>15/85</td>
<td>for animal cells</td>
</tr>
</tbody>
</table>

**NOTE** Additional aspects of the modified animals are classified in the groups A01K 2207/00 - A01K 2267/00

**WARNING**

From March 15, 2012 groups C12N 15/861 - C12N 15/869 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N 2710/00-C12N 2795/00

<table>
<thead>
<tr>
<th>CPC Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>15/8509</td>
<td>for producing genetically modified animals, e.g. transgenic</td>
</tr>
</tbody>
</table>

**WARNING**

From March 15, 2012 groups A01K 2207/00 - A01K 2267/00
15/873 . . . Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos

15/877 . . . Techniques for producing new mammalian cloned embryos

15/8771 . . . {Bovine embryos}
15/8772 . . . {Caprine embryos}
15/8773 . . . {Ovine embryos}
15/8775 . . . {Murine embryos}
15/8776 . . . {Primate embryos}
15/8777 . . . {Rabbit embryos}
15/8778 . . . {Swine embryos}
15/88 . . . using microencapsulation, e.g. using [amphiphile] liposome vesicle
15/89 . . . using microinjection
15/90 . . . [using biolistic methods]
15/902 . . . [using homologous recombination]
15/905 . . . [in yeast]
15/907 . . . [in mammalian cells]

2303/00 Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids

NOTE

Indexing codes of group C12N 2303/00 are only used in combination with group C12N 15/111

2310/00 Structure or type of the nucleic acid

2310/10 . . . Type of nucleic acid
2310/11 . . . Antisense
2310/111 . . . spanning the whole gene, or a large part of it
2310/113 . . . targeting other non-coding nucleic acids, e.g. antigomirs
2310/12 . . . catalytic nucleic acids, e.g. ribozymes
2310/121 . . . Hammerhead
2310/122 . . . Hairpin
2310/123 . . . Hepatitis delta
2310/124 . . . based on group I or II introns
2310/1241 . . . Tetrahymena
2310/126 . . . involving RNase P
2310/127 . . . DNAzymes
2310/128 . . . processing or releasing ribozyme
2310/13 . . . Decoys
2310/14 . . . interfering N.A.
2310/141 . . . MicroRNAs, miRNAs
2310/15 . . . Nucleic acids forming more than 2 strands, e.g. TFOS
2310/151 . . . more than 3 strands, e.g. tetrads, H-DNA
2310/152 . . . on a single-stranded target, e.g. fold-back TFOS
2310/153 . . . with the aid of a protein, e.g. recombinase
2310/16 . . . Aptamers
2310/17 . . . Immunomodulatory nucleic acids
2310/18 . . . acting by a non-sequence specific mechanism (other than C12N 2310/16 or C12N 2310/17)
2310/20 . . . involving clustered regularly interspaced short palindromic repeats (CRISPRs)
2310/30 . . . Chemical structure
2310/31 . . . of the backbone
2310/311 . . . Phosphotriesters
2310/312 . . . Phosphonates

2310/3125 . . . Methylphosphonates
2310/313 . . . Phosphorodithioates
2310/314 . . . Phosphoramidates
2310/3145 . . . with the nitrogen in 3' or 5'-position
2310/315 . . . Phosphorothioates
2310/316 . . . Phosphonothioates
2310/317 . . . with an inverted bond, e.g. a cap structure
2310/318 . . . where the PO2 is completely replaced, e.g. MMI or formacetal
2310/3181 . . . Peptide nucleic acid, PNA
2310/3183 . . . Dial linkers, e.g. glycols or panadepoloids
2310/319 . . . linked by 2'-5' linkages, i.e. having a free 3'-position
2310/32 . . . of the sugar
2310/321 . . . 2'-O-R Modification
2310/322 . . . 2'-R Modification
2310/323 . . . modified ring structure
2310/3231 . . . having an additional ring, e.g. LNA, ENA
2310/3233 . . . Morpholino-type ring
2310/3235 . . . having the O of the ribose replaced by another atom
2310/33 . . . of the base
2310/331 . . . Universal or degenerate base
2310/332 . . . Abasic residue
2310/333 . . . Modified A
2310/334 . . . Modified C
2310/3341 . . . 5-Methylcytosine
2310/335 . . . Modified T or U
2310/336 . . . Modified G
2310/337 . . . in alpha-anomeric form
2310/34 . . . Spatial arrangement of the modifications
2310/341 . . . Gapmers, i.e. of the type =========
2310/342 . . . Hemimers, i.e. of the type =========
2310/343 . . . having patterns, e.g. =========
2310/344 . . . Position-specific modifications, e.g. on every purine, at the 3'-end
2310/345 . . . having at least two different backbone modifications
2310/346 . . . having a combination of backbone and sugar modifications
2310/35 . . . Nature of the modification
2310/351 . . . Conjugate
2310/3511 . . . intercalating or cleaving agent
2310/3513 . . . Protein; Peptide
2310/3515 . . . Lipophilic moiety, e.g. cholesterol
2310/3517 . . . Marker; Tag
2310/3519 . . . Fusion with another nucleic acid
2310/352 . . . linked to the nucleic acid via a carbon atom
2310/3521 . . . Methyl
2310/3523 . . . Allyl
2310/3525 . . . MOE, methoxyethoxy
2310/3527 . . . Other alkyl chain
2310/3529 . . . Aromatic substituent
2310/353 . . . linked to the nucleic acid via an atom other than carbon
2310/3531 . . . Hydrogen
2310/3533 . . . Halogen
2310/3535 . . . Nitrogen
2310/3550 . . . Physical structure
2310/3551 . . . in polymeric form, e.g. multimers, concatamers
2310/3552 . . . branched
2310/3553 . . . partially self-complementary or closed
Applications; Uses

2320/00

- in screening processes
- for the determination of target sites, i.e. of active nucleic acids
- in functional genomics, i.e. for the determination of gene function
- in a process of directed evolution, e.g. SELEX, acquiring a new function
- Special therapeutic applications
- Combination therapy
- Special delivery means, e.g. tissue-specific
- Alteration of splicing
- Allele or polymorphism specific uses
- based on a specific dosage / administration regimen
- Methods for regulating/modulating their activity
- modulating the chemical stability, e.g. nuclease-resistance
- modulating the physical stability, e.g. GC-content
- reducing unwanted side-effects

Production

2330/00

- naturally occurring
- chemically synthesised
- Libraries, arrays
- Biochemical production, i.e. in a transformed host cell

2320/00 Specific components of cell culture medium

2500/02

- Atmosphere, e.g. low oxygen conditions
- Inorganic components
- Metals; Metal chelators (cobalamine C12N 2500/38)
- Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- Calcium; Ca chelators; Calcitonin
- Magnesium; Mg chelators
- Transition metals
- Zinc; Zn chelators (insulin-zinc complexes C12N 2501/33)
- Iron; Fe chelators; Transferrin
- Insulin-transferrin; Insulin-transferrin-selenium
- Organic components (metal chelators C12N 2500/10; calcitonin C12N 2500/14; transferrin C12N 2500/24)
- Amino acids
- other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
- Sugars
- Polysols, e.g. glycerin, inositol
- Lipids
- Vitamins
- Nucleotides, nucleosides, bases (cyclic nucleotides C12N 2501/01, anti-neoplastic drugs C12N 2501/06)
- Organic phosphate, e.g. beta glycerophosphate
- Thiols, e.g. mercaptoethanol

2500/02

- Amines, e.g. putrescine
- Soluble polymers, e.g. polyethylene glycol [PEG]
- Buffer, e.g. pH regulation, osmotic pressure
- DMSO
- Undefined extracts (conditioned medium C12N 2502/00)
- from bacteria
- from fungi, e.g. yeasts
- from plants
- from protozoa
- from animals
- from invertebrates
- from mammals
- Serum-free medium, which may still contain naturally-sourced components
- Medium free of human- or animal-derived components
- Protein-free medium and culture conditions
- Xeno-free medium and culture conditions
- Serum-free medium

WARNING

This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to C12N 2500/90 - C12N 2500/98

2501/00 Active agents used in cell culture processes, e.g. differentiation

NOTE

Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in C07K 14/00, but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.

2501/01

- Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
- Compounds acting on the NO pathway, e.g. nitrososarginine
- Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- Adjuvants
- Lipid A (MPA, MPL)
- Lipopolysaccharides [LPS]
- Muramyl peptides
- Immunostimulating oligonucleotides, e.g. CpG
- Anti-neoplastic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
- Modulators of histone acetylation
- Heat shock proteins
- Growth factors
- Insulin-like growth factors [IGF]
- Epidermal growth factor [EGF]
- Acidic fibroblast growth factor (aFGF, FGF-1)
- Basic fibroblast growth factor (bFGF, FGF-2)
Cytokines; Chemokines

Interleukins [IL]
- Colony stimulating factors (G-CSF, GM-CSF)
- Interleukins [IL]
- Interleukin-1 (IL-1)
- Interleukin-2 (IL-2)
- Interleukin-3 (IL-3)
- Interleukin-4 (IL-4)
- Interleukin-5 (IL-5)
- Interleukin-6 (IL-6)
- Interleukin-7 (IL-7)
- Interleukin-8 (IL-8)
- Interleukin-9 (IL-9)
- Interleukin-10 (IL-10)
- Interleukin-11 (IL-11)
- Interleukin-12 (IL-12)
- Interleukin-13 (IL-13)
- Interleukin-14 (IL-14)
- Interleukin-15 (IL-15)
- Interleukin-16 (IL-16)
- Interleukin-17 (IL-17)
- Interleukin-18 (IL-18)
- Interleukin-19 (IL-19)
- Interleukin-20 (IL-20)
- Interleukin-21 (IL-21)
- Interleukin-22 (IL-22)
- Interleukin-23 (IL-23)
- Interleukin-24 (IL-24)
- Interleukin-25 (IL-25)
- Interleukin-26 (IL-26)
- Interleukin-27 (IL-27)
- Interleukin-28 (IL-28)
- Interleukin-29 (IL-29)
- Interleukin-30 (IL-30)

Colony stimulating factors (G-CSF, GM-CSF)

- Interleukin-1 (IL-1)
- Interleukin-2 (IL-2)
- Interleukin-3 (IL-3)
- Interleukin-4 (IL-4)
- Interleukin-5 (IL-5)
- Interleukin-6 (IL-6)
- Interleukin-7 (IL-7)
- Interleukin-8 (IL-8)
- Interleukin-9 (IL-9)
- Interleukin-10 (IL-10)
- Interleukin-11 (IL-11)
- Interleukin-12 (IL-12)
- Interleukin-13 (IL-13)
- Interleukin-14 (IL-14)
- Interleukin-15 (IL-15)
- Interleukin-16 (IL-16)
- Interleukin-17 (IL-17)
- Interleukin-18 (IL-18)
- Interleukin-19 (IL-19)
- Interleukin-20 (IL-20)
- Interleukin-21 (IL-21)
- Interleukin-22 (IL-22)
- Interleukin-23 (IL-23)
- Interleukin-24 (IL-24)
- Interleukin-25 (IL-25)
- Interleukin-26 (IL-26)
- Interleukin-27 (IL-27)
- Interleukin-28 (IL-28)
- Interleukin-29 (IL-29)
- Interleukin-30 (IL-30)

Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10

- Vascular endothelial growth factor [VEGF]
- Activin; Inhibin; Mullerian inhibiting substance

Growth and differentiation factors [GDF]
- Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- Activin; Inhibin; Mullerian inhibiting substance

Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor

- Growth and differentiation factors [GDF]
- Heregulin, neu differentiation factor
- Cytokines; Chemokines
- Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
- Colony stimulating factors (G-CSF, GM-CSF)
- Interleukins [IL]
- Colony stimulating factors (G-CSF, GM-CSF)
- Interleukins [IL]
- Interleukin-1 (IL-1)
- Interleukin-2 (IL-2)
- Interleukin-3 (IL-3)
- Interleukin-4 (IL-4)
- Interleukin-5 (IL-5)
- Interleukin-6 (IL-6)
- Interleukin-7 (IL-7)
- Interleukin-8 (IL-8)
- Interleukin-9 (IL-9)
- Interleukin-10 (IL-10)
- Interleukin-11 (IL-11)
- Interleukin-12 (IL-12)
- Interleukin-13 (IL-13)
- Interleukin-14 (IL-14)
- Interleukin-15 (IL-15)
- Interleukin-16 (IL-16)
- Interleukin-17 (IL-17)
- Interleukin-18 (IL-18)
- Interleukin-19 (IL-19)
- Interleukin-20 (IL-20)
- Interleukin-21 (IL-21)
- Interleukin-22 (IL-22)
- Interleukin-23 (IL-23)
- Interleukin-24 (IL-24)
- Interleukin-25 (IL-25)
- Interleukin-26 (IL-26)
- Interleukin-27 (IL-27)
- Interleukin-28 (IL-28)
- Interleukin-29 (IL-29)
- Interleukin-30 (IL-30)

Brain-derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins

Tumour necrosis factors [TNF]
- Flt-3 ligand (CD135L, flk-2 ligand)

Cytokines; Chemokines

Interleukins [IL]
- Colony stimulating factors (G-CSF, GM-CSF)
- Interleukins [IL]
- Interleukin-1 (IL-1)
- Interleukin-2 (IL-2)
- Interleukin-3 (IL-3)
- Interleukin-4 (IL-4)
- Interleukin-5 (IL-5)
- Interleukin-6 (IL-6)
- Interleukin-7 (IL-7)
- Interleukin-8 (IL-8)
- Interleukin-9 (IL-9)
- Interleukin-10 (IL-10)
- Interleukin-11 (IL-11)
- Interleukin-12 (IL-12)
- Interleukin-13 (IL-13)
- Interleukin-14 (IL-14)
- Interleukin-15 (IL-15)
- Interleukin-16 (IL-16)
- Interleukin-17 (IL-17)
- Interleukin-18 (IL-18)
- Interleukin-19 (IL-19)
- Interleukin-20 (IL-20)
- Interleukin-21 (IL-21)
- Interleukin-22 (IL-22)
- Interleukin-23 (IL-23)
- Interleukin-24 (IL-24)
- Interleukin-25 (IL-25)
- Interleukin-26 (IL-26)
- Interleukin-27 (IL-27)
- Interleukin-28 (IL-28)
- Interleukin-29 (IL-29)
- Interleukin-30 (IL-30)

Platelet-derived growth factor [PDGF]

- Platelet-derived growth factor [PDGF]
- Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor

C12N

Transcription factors

Cell markers; Cell surface determinants

Regulators of apoptosis

Steroid hormones

Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases

Hedgehog proteins; Cyclopamine (inhibitor)
CPC - 2019.05

2501/065 . Nanog
2501/066 . c-Myc
2501/068 . Lin28
2501/065 . MicroRNA
2501/070 . Enzymes
2501/071 . Oxidoreductases (EC 1.)
2501/072 . Transfersases (EC 2.)(acytlation of histones C12N 2501/065)
2501/0724 . Glycosyltransferases (EC 2.4.)
2501/0727 . Kinases (EC 2.7.)
2501/073 . Hydrolases (EC 3.)
2501/0734 . Proteases (EC 3.4.)
2501/080 . Neurotransmitters; Neurohormones
2501/0805 . Acetylcholine
2501/081 . Adrenaline
2501/0815 . Dopamine
2501/082 . Histamine
2501/0825 . Serotonin (5-HT); Melatonine
2501/083 . Tachykinins, e.g. substance P
2501/0835 . Neuropeptide Y [NPY]; Peptide YY [PYY]
2501/084 . Excitatory amino acids
2501/0845 . Gamma amino butyric acid [GABA]
2501/085 . Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
2501/0855 . Corticotropin [ACTH]
2501/086 . Melanocyte-stimulating hormone [MSH]
2501/090 . Polysaccharides
2501/0905 . Hyaluronic acid
2501/091 . Heparin
2501/0998 . Proteins not provided for elsewhere

**NOTE**
Classification by pathway does not apply.

2501/0999 . Small molecules not provided for elsewhere

**NOTE**
Classification by pathway does not apply.

2502/00 Coculture with; Conditioned medium produced by
2502/02 . embryonic cells
2502/025 . extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
2502/03 . non-embryonic pluripotent stem cells
2502/04 . germ cells
2502/07 . endocrine cells
2502/072 . adrenal cells
2502/074 . pinealocytes
2502/076 . pituitary cells
2502/078 . thyroid, parathyroid cells
2502/08 . cells of the nervous system
2502/081 . neurons
2502/083 . sensory transducers
2502/085 . eye cells
2502/086 . glial cells
2502/088 . neural stem cells
2502/09 . epidermal cells, skin cells, oral mucosa cells
2502/091 . melanocytes
2502/092 . hair cells
2502/094 . keratinocytes
2502/095 . mammary cells
2502/097 . oral mucosa cells
2502/098 . cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands
2502/11 . blood or immune system cells
2502/1107 . B cells
2502/1114 . T cells
2502/1121 . Dendritic cells
2502/1128 . Erythrocytes
2502/1135 . Granulocytes
2502/1142 . Osteoclasts
2502/115 . Platelets, megakaryocytes
2502/1157 . Monocytes, macrophages
2502/1164 . NK cells
2502/1171 . Haematopoietic stem cells
2502/1178 . Spleen cells
2502/1185 . Thymus cells
2502/1192 . Lymphatic cells
2502/1203 . connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
2502/1305 . Adipocytes
2502/1311 . Osteocytes, osteoblasts, odontoblasts
2502/1317 . Chondrocytes
2502/1323 . Adult fibroblasts
2502/1329 . Cardiomyocytes
2502/1335 . Skeletal muscle cells, myocytes, myoblasts, myotubes
2502/1341 . Tenocytes, cells from tendons and ligaments
2502/1347 . Smooth muscle cells
2502/1352 . Mesenchymal stem cells
2502/1358 . Bone marrow mesenchymal stem cells (BM-MSC)
2502/1364 . Dental pulp stem cells, dental follicle stem cells
2502/137 . Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood
2502/1376 . Mesenchymal stem cells from hair follicles
2502/1382 . Adipose-derived stem cells [ADSC], adipose stromal stem cells
2502/1388 . Mesenchymal stem cells from other natural sources
2502/1394 . Bone marrow stromal cells; whole marrow
2502/14 . hepatocytes
2502/22 . pancreatic cells
2502/23 . Gastro-intestinal tract cells
2502/24 . Genital tract cells, non-germinal cells from gonads
2502/243 . Cells of the female genital tract, non-germinal ovarian cells
2502/246 . Cells of the male genital tract, non-germinal testis cells
2502/25 . Urinary tract cells, renal cells
2502/253 . Bladder cells
2502/256 . Renal cells
2502/27 . Lung cells, respiratory tract cells
2502/28 . Vascular endothelial cells
2502/30 . tumour cells
2502/45 . Artificially induced pluripotent stem cells
2502/50 . invertebrate cells
2502/70 . Non-animal cells
2502/99 . genetically modified cells

**NOTE**
Use C12N 2501/00 to index the expressed products.

2503/00 Use of cells in diagnostics
Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells

NOTE

This scheme indexes the starting point of a differentiation process and is used in combination with classification in C12N 5/06 for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed.

Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells

- from embryonic cells
- from extra-embryonic cells, e.g. trophoblast, placenta
- from non-embryonic pluripotent stem cells
- from germ cells
- from endocrine cells
- from adrenal cells
- from pinealocytes
- from pituitary cells
- from thyroid, parathryoid cells
- from cells of the nervous system
- from epidermal cells, from skin cells, from oral mucosa cells
- from melanocytes
- from hair cells
- from keratinocytes
- from mammary cells
- from oral mucosa cells
- from cells of secrertry glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
- from blood or immune system cells
- from monocytes, from macrophages
- from connective tissue cells, from mesenchymal cells
- from adult fibroblasts
- from cardiomyocytes
- from skeletal muscle cells
- from tenocytes
- from smooth muscle cells
- from mesenchymal stem cells
- from bone marrow mesenchymal stem cells (BM-MSC)
- from dental pulp or dental follicle stem cells
- from blood-bone mesenchymal stem cells, e.g. MSC from umbilical blood
- from mesenchymal stem cells derived from hair follicles
- from adipose-derived stem cells [ADSC], from adipose stromal stem cells
- from mesenchymal stem cells from other natural sources
- from hepatocytes
- from pancreatic cells
- from cells of the gastro-intestinal tract
- from cells of the genital tract, from non-germinal gonad cells
- from cells of the female genital tract cells, from non-germinal ovarian cells

- from cells of the male genital tract cells, from non-germinal testis cells
- from renal cells, from cells of the urinary tract
- from lung cells, from cells of the respiratory tract
- from vascular endothelial cells
- from cancer cells, e.g. reversion of tumour cells

NOTE

Unless the tumorigenic phenotype is totally reversed, the end product is still classified under C12N 5/0693.

- from artificially induced pluripotent stem cells

- Methods for the dissociation of cells, e.g. specific use of enzymes
- Mechanical dissociation
- Genetically modified cells
- Cells for production
- Immortalised cells
- Cells for large scale production
- 3D culture
- Cells related to new breeds of animals
- Cells from transgenic animals
- Cells produced using nuclear transfer
- Conditioning of cells for in vitro fecondation or nuclear transfer

Culture process characterised by the use of hydrostatic pressure, flow or shear forces
- Sound, e.g. ultrasounds

Culture process characterised by temperature

Culture process characterised by gravity, e.g. microgravity

Culture process characterised by the use of mechanical forces, e.g. strain, vibration
- Stimulation by light

Microcarriers

Supports or coatings for cell culture, characterised by material
- Mineral substrates
- Glass
- Ceramic
- Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
- Small organic molecules
- Synthetic polymers (thermoreactive polymers, e.g. PNIPAm, C12N 2539/10)
- Polyllysine, polyornithine
- Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
- Proteins
- Fibronectin; Laminin
- Collagen; Gelatin
- Fibrin; Thrombin
- Polysaccharides
2533/72 . . Chitin, chitosan
2533/74 . . Alginate
2533/76 . . Agarose, agar-agar
2533/78 . . Cellulose
2533/80 . . Hyaluronan
2533/90 . . Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
2533/92 . . Amnion; Decellularised dermis or mucosa

2535/00 Supports or coatings for cell culture characterised by topography
2535/10 . Patterned coating

2537/00 Supports and/or coatings for cell culture characterised by physical or chemical treatment
2537/10 . Cross-linking

2539/00 Supports and/or coatings for cell culture characterised by properties
2539/10 . Coating allowing for selective detachment of cells, e.g. thermoreactive coating

2700/00 Viruses

2710/00 dsDNA Viruses (not used)
2710/00011 . dsDNA Viruses
2710/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/00023 . . Virus like particles [VLP]
2710/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/00041 . . Use of virus, viral particle or viral elements as a vector
2710/00042 . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/00043 . . viral genome or elements thereof as genetic vector
2710/00044 . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/00051 . . Methods of production or purification of viral material
2710/00052 . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/00053 . . Special targeting system for viral vectors
2710/00054 . . Methods of inactivation or attenuation
2710/00061 . . Methods of inactivation or attenuation
2710/00062 . . by genetic engineering
2710/00063 . . by chemical treatment
2710/00064 . . by serial passage
2710/00071 . . Demonstrated in vivo effect
2710/00088 . . For redistribution
2710/10011 . . Adenoviridae
2710/10021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/10022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/10023 . . Virus like particles [VLP]
2710/10031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/10034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/10041 . . Use of virus, viral particle or viral elements as a vector
2710/10042 . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/10043 . . viral genome or elements thereof as genetic vector
2710/10044 . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/10045 . . Special targeting system for viral vectors
2710/10051 . . Methods of production or purification of viral material
2710/10052 . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/10053 . . Special targeting system for viral vectors
2710/10061 . . Methods of inactivation or attenuation
2710/10062 . . by genetic engineering
2710/10063 . . by chemical treatment
2710/10064 . . by serial passage
2710/10071 . . Demonstrated in vivo effect
2710/10088 . . For redistribution
2710/10111 . . Adenovirus, e.g. ovine adenovirus D
2710/10121 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/10122 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/10123 . . Virus like particles [VLP]
2710/10131 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10132 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10133 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/10134 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/10141 . . Use of virus, viral particle or viral elements as a vector
2710/10142 . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/10143 . . viral genome or elements thereof as genetic vector
2710/10144 . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/10145 . . Special targeting system for viral vectors
2710/10151 . . Methods of production or purification of viral material
2710/10152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/10161 . . . . . Methods of inactivation or attenuation
2710/10162 . . . . . by genetic engineering
2710/10163 . . . . . by chemical treatment
2710/10164 . . . . . by serial passage
2710/10171 . . . . . Demonstrated in vivo effect
2710/10188 . . . . . For redistribution
2710/10211 . . . . . Aviadenovirus, e.g. fowl adenovirus A
2710/10221 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/10222 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/10223 . . . . . Virus like particles [VLP]
2710/10231 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10232 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10233 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/10234 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/10241 . . . . . Use of virus, viral particle or viral elements as a vector
2710/10242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/10243 . . . . . viral genome or elements thereof as genetic vector
2710/10244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/10245 . . . . . Special targeting system for viral vectors
2710/10251 . . . . . Methods of production or purification of viral material
2710/10252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/10261 . . . . . Methods of inactivation or attenuation
2710/10262 . . . . . by genetic engineering
2710/10263 . . . . . by chemical treatment
2710/10264 . . . . . by serial passage
2710/10271 . . . . . Demonstrated in vivo effect
2710/10288 . . . . . For redistribution
2710/10311 . . . . . Mastadenovirus, e.g. human or simian adenoviruses
2710/10321 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/10322 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/10323 . . . . . Virus like particles [VLP]
2710/10331 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10332 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10333 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/10334 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/10341 . . . . . Use of virus, viral particle or viral elements as a vector
2710/10342 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/10343 . . . . . viral genome or elements thereof as genetic vector
2710/10344 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/10345 . . . . . Special targeting system for viral vectors
2710/10351 . . . . . Methods of production or purification of viral material
2710/10352 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/10361 . . . . . Methods of inactivation or attenuation
2710/10362 . . . . . by genetic engineering
2710/10363 . . . . . by chemical treatment
2710/10364 . . . . . by serial passage
2710/10371 . . . . . Demonstrated in vivo effect
2710/10388 . . . . . For redistribution
2710/12011 . . . . . Astfarviridae
2710/12021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/12022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/12023 . . . . . Virus like particles [VLP]
2710/12031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/12032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/12033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/12034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/12041 . . . . . Use of virus, viral particle or viral elements as a vector
2710/12042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/12043 . . . . . viral genome or elements thereof as genetic vector
2710/12044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/12045 . . . . . Special targeting system for viral vectors
2710/12051 . . . . . Methods of production or purification of viral material
2710/12052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/12061 . . . . . Methods of inactivation or attenuation
2710/12062 . . . . . by genetic engineering
2710/12063 . . . . . by chemical treatment
2710/12064 . . . . . by serial passage
2710/12071 . . . . . Demonstrated in vivo effect
2710/12088 . . . . . For redistribution
2710/14011 . . . . . Baculoviridae
2710/14041 . . . Use of virus, viral particle or viral elements as a vector
2710/14042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/14043 . . . viral genome or elements thereof as genetic vector
2710/14044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/14045 . . . Special targeting system for viral vectors
2710/14051 . . . Methods of production or purification of viral material
2710/14052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/14061 . . . Methods of inactivation or attenuation
2710/14062 . . . by genetic engineering
2710/14063 . . . by chemical treatment
2710/14064 . . . by serial passage
2710/14071 . . . Demonstrated in vivo effect
2710/14088 . . . For redistribution
2710/14111 . . . Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
2710/14121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/14122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/14123 . . . Virus like particles [VLP]
2710/14131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/14132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/14133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/14134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/14141 . . . Use of virus, viral particle or viral elements as a vector
2710/14142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/14143 . . . viral genome or elements thereof as genetic vector
2710/14144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/14145 . . . Special targeting system for viral vectors
2710/14151 . . . Methods of production or purification of viral material
2710/14152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/14161 . . . Methods of inactivation or attenuation
2710/14162 . . . by genetic engineering
2710/14163 . . . by chemical treatment
2710/14164 . . . by serial passage
2710/14171 . . . Demonstrated in vivo effect
2710/14188 . . . For redistribution
2710/16011 . . . Herpesviridae
2710/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16023 . . . Virus like particles [VLP]
2710/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16041 . . . Use of virus, viral particle or viral elements as a vector
2710/16042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16043 . . . viral genome or elements thereof as genetic vector
2710/16044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16045 . . . Special targeting system for viral vectors
2710/16051 . . . Methods of production or purification of viral material
2710/16052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/16061 . . . Methods of inactivation or attenuation
2710/16062 . . . by genetic engineering
2710/16063 . . . by chemical treatment
2710/16064 . . . by serial passage
2710/16071 . . . Demonstrated in vivo effect
2710/16088 . . . For redistribution
2710/16111 . . . Cytomegalovirus, e.g. human herpesvirus 5
2710/16121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16123 . . . Virus like particles [VLP]
2710/16131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16141 . . . . Use of virus, viral particle or viral elements as a vector
2710/16142 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16143 . . . . . . viral genome or elements thereof as genetic vector
2710/16144 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16145 . . . . . . Special targeting system for viral vectors
2710/16151 . . . . . . Methods of production or purification of viral material
2710/16152 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/16161 . . . . Methods of inactivation or attenuation
2710/16162 . . . . . . by genetic engineering
2710/16163 . . . . . . by chemical treatment
2710/16164 . . . . . . by serial passage
2710/16171 . . . . . . Demonstrated in vivo effect
2710/16188 . . . . . . For redistribution
2710/16211 . . . . Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
2710/16221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16223 . . . . Virus like particles [VLP]
2710/16231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16232 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16233 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16234 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16241 . . . . Use of virus, viral particle or viral elements as a vector
2710/16242 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16243 . . . . . . viral genome or elements thereof as genetic vector
2710/16244 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16245 . . . . . . Special targeting system for viral vectors
2710/16251 . . . . . . Methods of production or purification of viral material
2710/16252 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/16261 . . . . Methods of inactivation or attenuation
2710/16262 . . . . . . by genetic engineering
2710/16263 . . . . . . by chemical treatment
2710/16264 . . . . . . by serial passage
2710/16271 . . . . . . Demonstrated in vivo effect
2710/16288 . . . . . . For redistribution
2710/16311 . . . . Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
2710/16321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16323 . . . . Virus like particles [VLP]
2710/16331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16332 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16333 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16334 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16341 . . . . Use of virus, viral particle or viral elements as a vector
2710/16342 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16343 . . . . . . viral genome or elements thereof as genetic vector
2710/16344 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16345 . . . . Special targeting system for viral vectors
2710/16351 . . . . Methods of production or purification of viral material
2710/16352 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/16361 . . . . . . Methods of inactivation or attenuation
2710/16362 . . . . . . by genetic engineering
2710/16363 . . . . . . by chemical treatment
2710/16364 . . . . . . by serial passage
2710/16371 . . . . . . Demonstrated in vivo effect
2710/16388 . . . . . . For redistribution
2710/16411 . . . . Rhabdovirus, e.g. human herpesvirus 8
2710/16421 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16422 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16423 . . . . Virus like particles [VLP]
2710/16431 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16432 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16433 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16434 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16441 . . . . Use of virus, viral particle or viral elements as a vector
2710/16442 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16443 . . . . . . viral genome or elements thereof as genetic vector
2710/16444 . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16445 . . . . . . . Special targeting system for viral vectors
2710/16451 . . . . . . . Methods of production or purification of viral material
2710/16452 . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/16461 . . . . . . . Methods of inactivation or attenuation
2710/16462 . . . . . . . by genetic engineering
2710/16463 . . . . . . . by chemical treatment
2710/16464 . . . . . . . by serial passage
2710/16471 . . . . . . . Demonstrated in vivo effect
2710/16488 . . . . . . . For redistribution
2710/16511 . . . . . . . Roseolovirus, e.g. human herpesvirus 6, 7
2710/16521 . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16522 . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16523 . . . . . . . Virus like particles [VLP]
2710/16531 . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16532 . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16533 . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16534 . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral
2710/16541 . . . . . . . Use of virus, viral particle or viral elements as a vector
2710/16542 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16543 . . . . . . . viral genome or elements thereof as genetic vector
2710/16544 . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16545 . . . . . . . Special targeting system for viral vectors
2710/16551 . . . . . . . Methods of production or purification of viral material
2710/16552 . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/16561 . . . . . . . Methods of inactivation or attenuation
2710/16562 . . . . . . . by genetic engineering
2710/16563 . . . . . . . by chemical treatment
2710/16564 . . . . . . . by serial passage
2710/16571 . . . . . . . Demonstrated in vivo effect
2710/16588 . . . . . . . For redistribution
2710/16611 . . . . . . . Simplexvirus, e.g. human herpesvirus 1, 2
2710/16621 . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16622 . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16623 . . . . . . . Virus like particles [VLP]
2710/16631 . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16632 . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16633 . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16634 . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral
2710/16641 . . . . . . . Use of virus, viral particle or viral elements as a vector
2710/16642 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16643 . . . . . . . viral genome or elements thereof as genetic vector
2710/16644 . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16645 . . . . . . . Special targeting system for viral vectors
2710/16651 . . . . . . . Methods of production or purification of viral material
2710/16652 . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/16661 . . . . . . . Methods of inactivation or attenuation
2710/16662 . . . . . . . by genetic engineering
2710/16663 . . . . . . . by chemical treatment
2710/16664 . . . . . . . by serial passage
2710/16671 . . . . . . . Demonstrated in vivo effect
2710/16688 . . . . . . . For redistribution
2710/16711 . . . . . . . Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
2710/16721 . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16722 . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16723 . . . . . . . Virus like particles [VLP]
2710/16731 . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16732 . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16733 . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16734 . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral
2710/16741 . . . . . . . Use of virus, viral particle or viral elements as a vector
2710/16742 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16743 . . . . . . . viral genome or elements thereof as genetic vector
2710/16744 . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16745 . . . . . . . Special targeting system for viral vectors
2710/16751 . . . . . . . Methods of production or purification of viral material
2710/16752 . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/16761 . . . . . . . Methods of inactivation or attenuation
2710/16762 . . . . . . . by genetic engineering
2710/16763 . . . . . . . by chemical treatment
2710/16764 . . . . . . . by serial passage
2710/16771  . . . . Demonstrated in vivo effect
2710/16788  . . . . For redistribution
2710/18011  . . . . Nimaviridae
2710/18021  . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/18022  . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/18023  . . . . Virus like particles [VLP]
2710/18031  . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/18032  . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/18033  . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/18034  . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/18041  . . . . Use of virus, viral particle or viral elements as a vector
2710/18042  . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/18043  . . . . viral genome or elements thereof as genetic vector
2710/18044  . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/18045  . . . . Special targeting system for viral vectors
2710/18046  . . . . Methods of production or purification of viral material
2710/18052  . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/18061  . . . . Methods of inactivation or attenuation
2710/18062  . . . . by genetic engineering
2710/18063  . . . . by chemical treatment
2710/18064  . . . . by serial passage
2710/18071  . . . . Demonstrated in vivo effect
2710/18088  . . . . For redistribution
2710/22011  . . . . Papillomaviridae
2710/22021  . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/22031  . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/22041  . . . . Use of virus, viral particle or viral elements as a vector
2710/22042  . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/22043  . . . . viral genome or elements thereof as genetic vector
2710/22044  . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/22045  . . . . Special targeting system for viral vectors
2710/22051  . . . . Methods of production or purification of viral material
2710/22052  . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/22061  . . . . Methods of inactivation or attenuation
2710/22062  . . . . by genetic engineering
2710/22063  . . . . by chemical treatment
2710/22064  . . . . by serial passage
2710/22071  . . . . Demonstrated in vivo effect
2710/22088  . . . . For redistribution
2710/24011  . . . . Poxviridae
2710/24021  . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/24022  . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/24031  . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/24032  . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Orthopoxvirus, e.g. vaccinia virus, variola

For redistribution

Demonstrated in vivo

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Orthopoxvirus, e.g. vaccinia virus, variola

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Parapoxvirus, e.g. Orf virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

dsRNA Viruses (not used)

dsRNA Viruses

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

viral genome or elements thereof as genetic vector
C12N

2720/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/00045 . . . Special targeting system for viral vectors
2720/00051 . . . Methods of production or purification of viral material
2720/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2720/00061 . . . Methods of inactivation or attenuation
2720/00062 . . by genetic engineering
2720/00063 . . by chemical treatment
2720/00064 . . by serial passage
2720/00071 . . Demonstrated in vivo effect
2720/00088 . . For redistribution
2720/10011 . . Bimaviridae
2720/10021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/10022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/10023 . . Virus like particles [VLP]
2720/10031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/10032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/10033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/10034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/10041 . . Use of virus, viral particle or viral elements as a vector
2720/10042 . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/10043 . . viral genome or elements thereof as genetic vector
2720/10044 . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/10045 . . Special targeting system for viral vectors
2720/10051 . . Methods of production or purification of viral material
2720/10052 . . relating to complementing cells and packaging systems for producing virus or viral particles
2720/10061 . . Methods of inactivation or attenuation
2720/10062 . . by genetic engineering
2720/10063 . . by chemical treatment
2720/10064 . . by serial passage
2720/10071 . . Demonstrated in vivo effect
2720/10088 . . For redistribution
2720/12011 . . Reoviridae
2720/12021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/12022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/12023 . . Virus like particles [VLP]
2720/12031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/12032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/12033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/12034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12041 . . Use of virus, viral particle or viral elements as a vector
2720/12042 . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/12043 . . viral genome or elements thereof as genetic vector
2720/12044 . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/12045 . . Special targeting system for viral vectors
2720/12051 . . Methods of production or purification of viral material
2720/12052 . . relating to complementing cells and packaging systems for producing virus or viral particles
2720/12061 . . Methods of inactivation or attenuation
2720/12062 . . by genetic engineering
2720/12063 . . by chemical treatment
2720/12064 . . by serial passage
2720/12071 . . Demonstrated in vivo effect
2720/12088 . . For redistribution
2720/12111 . . Orbivirus, e.g. bluetongue virus
2720/12121 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/12122 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/12123 . . Virus like particles [VLP]
2720/12131 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/12132 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/12133 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/12134 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12141 . . Use of virus, viral particle or viral elements as a vector
2720/12142 . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/12143 . . viral genome or elements thereof as genetic vector
2720/12144 . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/12145 . . Special targeting system for viral vectors
2720/12151 . . Methods of production or purification of viral material
2720/12152 . . relating to complementing cells and packaging systems for producing virus or viral particles
2720/12161 . . Methods of inactivation or attenuation
2720/12162 . . by genetic engineering
2720/12163 . . by chemical treatment
2720/12164 . . by serial passage
2720/12171 . . Demonstrated in vivo effect
2720/12188 . . . . . . . . . . For redistribution
2720/12211 . . . . . . . . . . Orthoreovirus, e.g. mammalian orthoreovirus
2720/12221 . . . . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/12222 . . . . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/12223 . . . . . . . . . . Virus like particles [VLP]
2720/12231 . . . . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/12232 . . . . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/12233 . . . . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/12234 . . . . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12241 . . . . . . . . . . Use of virus, viral particle or viral elements as a vector
2720/12242 . . . . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/12243 . . . . . . . . . . viral genome or elements thereof as genetic vector
2720/12244 . . . . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/12245 . . . . . . . . . . Special targeting system for viral vectors
2720/12251 . . . . . . . . . . Methods of production or purification of viral material
2720/12252 . . . . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2720/12261 . . . . . . . . . . Methods of inactivation or attenuation
2720/12262 . . . . . . . . . . by genetic engineering
2720/12263 . . . . . . . . . . by chemical treatment
2720/12264 . . . . . . . . . . by serial passage
2720/12271 . . . . . . . . . . Demonstrated in vivo effect
2720/12288 . . . . . . . . . . For redistribution
2720/12311 . . . . . . . . . . Rotavirus, e.g. rotavirus A
2720/12321 . . . . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/12322 . . . . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/12323 . . . . . . . . . . Virus like particles [VLP]
2720/12331 . . . . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/12332 . . . . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/12333 . . . . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/12334 . . . . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12341 . . . . . . . . . . Use of virus, viral particle or viral elements as a vector
2720/12342 . . . . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/12343 . . . . . . . . . . viral genome or elements thereof as genetic vector
2720/12344 . . . . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/12345 . . . . . . . . . . Special targeting system for viral vectors
2720/12351 . . . . . . . . . . Methods of production or purification of viral material
2720/12352 . . . . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2720/12361 . . . . . . . . . . Methods of inactivation or attenuation
2720/12362 . . . . . . . . . . by genetic engineering
2720/12363 . . . . . . . . . . by chemical treatment
2720/12364 . . . . . . . . . . by serial passage
2720/12371 . . . . . . . . . . Demonstrated in vivo effect
2720/12388 . . . . . . . . . . For redistribution
2730/000011 . . . . . . . . . . Reverse Transcribing DNA Viruses
2730/000021 . . . . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2730/000022 . . . . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2730/000023 . . . . . . . . . . Virus like particles [VLP]
2730/000031 . . . . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2730/000032 . . . . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2730/000033 . . . . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2730/000034 . . . . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2730/000041 . . . . . . . . . . Use of virus, viral particle or viral elements as a vector
2730/000042 . . . . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2730/000043 . . . . . . . . . . viral genome or elements thereof as genetic vector
2730/000044 . . . . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2730/000045 . . . . . . . . . . Special targeting system for viral vectors
2730/000051 . . . . . . . . . . Methods of production or purification of viral material
2730/000052 . . . . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2730/000061 . . . . . . . . . . Methods of inactivation or attenuation
2730/000062 . . . . . . . . . . by genetic engineering
2730/000063 . . . . . . . . . . by chemical treatment
2730/000064 . . . . . . . . . . by serial passage
2730/000071 . . . . . . . . . . Demonstrated in vivo effect
2730/000088 . . . . . . . . . . For redistribution
2730/100111 . . . . . . . . . . Hepadnaviridae
2730/100211 . . . . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2730/100221 . . . . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2730/100231 . . . . . . . . . . Virus like particles [VLP]
2730/100311 . . . . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Reverse Transcribing DNA Viruses (not used)
2730/000001 . . . . . . . . . . Reverse Transcribing DNA Viruses
2730/000023 . . . . . . . . . . Virus like particles [VLP]
Orthohepadnavirus, e.g. hepatitis B virus

For redistribution
effect
Demonstrated in vivo

Methods of inactivation or attenuation
material

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation
by genetic engineering
by chemical treatment
by serial passage
Demonstrated in vivo effect
For redistribution
Orthohepadnavirus, e.g. hepatitis B virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Viruses as such, e.g. new isolates, mutants or their genomic sequences

by serial passage
Demonstrated in vivo effect
For redistribution
Retroviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

by serial passage
by chemical treatment
by serial passage
Demonstrated in vivo effect
For redistribution
Retroviridae
Alpharetrovirus, e.g. avian leucosis virus

Betaretrovirus, e.g. mouse mammary tumour virus

Virus like particles [VLP]

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]
<table>
<thead>
<tr>
<th>Application</th>
<th>Claims</th>
</tr>
</thead>
<tbody>
<tr>
<td>2740/13062</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2740/13063</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2740/13064</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2740/13071</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2740/13088</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2740/14011</td>
<td>Deltaretrovirus, e.g. bovine leukemia virus</td>
</tr>
<tr>
<td>2740/14021</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2740/14022</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2740/14023</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2740/14031</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2740/14032</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2740/14033</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2740/14034</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2740/14041</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2740/14042</td>
<td>virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2740/14043</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2740/14044</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2740/14045</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2740/14051</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2740/14052</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2740/14061</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2740/14062</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2740/14063</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2740/14064</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2740/14071</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2740/14088</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2740/15011</td>
<td>Lentivirus, not HIV, e.g. FIV, SIV</td>
</tr>
<tr>
<td>2740/15021</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2740/15022</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2740/15023</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2740/15031</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2740/15032</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2740/15033</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2740/15034</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2740/15041</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2740/15042</td>
<td>virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2740/15043</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2740/15044</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2740/15045</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2740/15051</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2740/15052</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2740/15061</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2740/15062</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2740/15063</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2740/15064</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2740/15071</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2740/15088</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2740/16011</td>
<td>Human Immunodeficiency Virus, HIV</td>
</tr>
<tr>
<td>2740/16021</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2740/16022</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2740/16023</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2740/16031</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2740/16032</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2740/16033</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2740/16034</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2740/16041</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2740/16042</td>
<td>virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2740/16043</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2740/16044</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2740/16045</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2740/16051</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2740/16052</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2740/16061</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2740/16062</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2740/16063</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2740/16064</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2740/16071</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2740/16088</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2740/16111</td>
<td>concerning HIV env</td>
</tr>
<tr>
<td>2740/16122</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2740/16134</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2740/16171</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2740/16188</td>
<td>For redistribution</td>
</tr>
</tbody>
</table>
C12N

2740/16211 . . . . . . concerning HIV gagpol
2740/16222 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/16234 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/16271 . . . . . . Demonstrated in vivo effect
2740/16288 . . . . . . For redistribution
2740/16311 . . . . . . concerning HIV regulatory proteins
2740/16322 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/16334 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/16371 . . . . . . Demonstrated in vivo effect
2740/16388 . . . . . . For redistribution
2740/17011 . . . . . . Spumavirus, e.g. chimpanzee foamy virus
2740/17021 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/17022 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/17023 . . . . . . Virus like particles [VLP]
2740/17031 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/17032 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/17033 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/17034 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/17041 . . . . . . Use of virus, viral particle or viral elements as a vector
2740/17042 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/17043 . . . . . . viral genome or elements thereof as genetic vector
2740/17044 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/17045 . . . . . . Special targeting system for viral vectors
2740/17051 . . . . . . Methods of production or purification of viral material
2740/17052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2740/17061 . . . . . . Methods of inactivation or attenuation
2740/17062 . . . . . . by genetic engineering
2740/17063 . . . . . . by chemical treatment
2740/17064 . . . . . . by serial passage
2740/17071 . . . . . . Demonstrated in vivo effect
2740/17088 . . . . . . For redistribution

2750/00 . . . ssDNA Viruses (not used)
2750/00011 . . . ssDNA Viruses
2750/00021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/00022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/00023 . . . Virus like particles [VLP]
2750/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/00041 . . . Use of virus, viral particle or viral elements as a vector
2750/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/00043 . . . viral genome or elements thereof as genetic vector
2750/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/00045 . . . Special targeting system for viral vectors
2750/00051 . . . Methods of production or purification of viral material
2750/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2750/00061 . . . Methods of inactivation or attenuation
2750/00062 . . . by genetic engineering
2750/00063 . . . by chemical treatment
2750/00064 . . . by serial passage
2750/00071 . . . Demonstrated in vivo effect
2750/00088 . . . For redistribution
2750/10011 . . . Circoviridae
2750/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/10023 . . . Virus like particles [VLP]
2750/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/10041 . . . Use of virus, viral particle or viral elements as a vector
2750/10042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/10043 . . . viral genome or elements thereof as genetic vector
2750/10044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/10045 . . . Special targeting system for viral vectors
2750/10051 . . . Methods of production or purification of viral material
2750/10052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2750/10061 . . . Methods of inactivation or attenuation
2750/10062 . . . by genetic engineering
2750/10063 . . . by chemical treatment
2750/10064 . . . by serial passage
2750/10071 . . . Demonstrated in vivo effect
2750/10088 . . . For redistribution
2750/12011 . . . Geminiviridae
2750/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/12023 . . . Virus like particles [VLP]
2750/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/12041 . . . Use of virus, viral particle or viral elements as a vector
2750/12042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/12043 . . . viral genome or elements thereof as genetic vector
2750/12044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/12045 . . . Special targeting system for viral vectors
2750/12051 . . . Methods of production or purification of viral material
2750/12052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2750/12061 . . . Methods of inactivation or attenuation
2750/12062 . . . by genetic engineering
2750/12063 . . . by chemical treatment
2750/12064 . . . by serial passage
2750/12071 . . . Demonstrated in vivo effect
2750/12088 . . . For redistribution
2750/14044 . . . viral genome or elements thereof as genetic vector
2750/14045 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/14046 . . . by genetic engineering
2750/14047 . . . by chemical treatment
2750/14048 . . . by serial passage
2750/14051 . . . Methods of production or purification of viral material
2750/14052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2750/14061 . . . Methods of inactivation or attenuation
2750/14062 . . . by genetic engineering
2750/14063 . . . by chemical treatment
2750/14064 . . . by serial passage
2750/14071 . . . Demonstrated in vivo effect
2750/14088 . . . For redistribution
2750/14111 . . . Dependovirus, e.g. adenoassociated viruses
2750/14121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/14122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/14123 . . . Virus like particles [VLP]
2750/14131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/14132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/14133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/14134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/14141 . . . Use of virus, viral particle or viral elements as a vector
2750/14142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/14143 . . . viral genome or elements thereof as genetic vector
2750/14144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/14145 . . . Special targeting system for viral vectors
2750/14151 . . . Methods of production or purification of viral material
2750/14152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2750/14161 . . . Methods of inactivation or attenuation
2750/14162 . . . by genetic engineering
2750/14163 . . . by chemical treatment
2750/14164 . . . by serial passage
2750/14171 . . . Demonstrated in vivo effect
2750/14188 . . . For redistribution
2750/14211 . . . Erythrovirus, e.g. B19 virus
2750/14221 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/14222 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/14223 . . . Virus like particles [VLP]
2750/14231 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/14232 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/14233 . . . viral genome or elements thereof as genetic vector
2750/14232 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/14233 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/14234 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/14241 . . . . . . Use of virus, viral particle or viral elements as a vector
2750/14242 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/14243 . . . . . . . viral genome or elements thereof as genetic vector
2750/14244 . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/14245 . . . . . . . Special targeting system for viral vectors
2750/14251 . . . . . . . Methods of production or purification of viral material
2750/14252 . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2750/14261 . . . . . . . Methods of inactivation or attenuation
2750/14262 . . . . . . . by genetic engineering
2750/14263 . . . . . . . by chemical treatment
2750/14264 . . . . . . . by serial passage
2750/14271 . . . . . . . Demonstrated in vivo effect
2750/14288 . . . . . . . For redistribution
2750/14311 . . . . . . Parvovirus, e.g. minute virus of mice
2750/14321 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/14322 . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/14323 . . . . . . . Virus like particles [VLP]
2750/14331 . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/14332 . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/14333 . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/14334 . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/14341 . . . . . . . Use of virus, viral particle or viral elements as a vector
2750/14342 . . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/14343 . . . . . . . . viral genome or elements thereof as genetic vector
2750/14344 . . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/14345 . . . . . . . Special targeting system for viral vectors
2750/14351 . . . . . . . Methods of production or purification of viral material
2750/14352 . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2750/14361 . . . . . . . Methods of inactivation or attenuation
2750/14362 . . . . . . . by genetic engineering
2750/14363 . . . . . . . by chemical treatment
2750/14364 . . . . . . . by serial passage
2750/14371 . . . . . . . Demonstrated in vivo effect
2750/14388 . . . . . . . For redistribution
2760/00 ssRNA Viruses negative-sense (not used)
2760/00011 . ssRNA Viruses negative-sense
2760/00021 . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/00022 . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/00023 . Virus like particles [VLP]
2760/00031 . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/00032 . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/00033 . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/00034 . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/00041 . Use of virus, viral particle or viral elements as a vector
2760/00042 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/00043 . . . . . . . viral genome or elements thereof as genetic vector
2760/00044 . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/00045 . . . . . . . Special targeting system for viral vectors
2760/00051 . . . . . . . Methods of production or purification of viral material
2760/00052 . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/00061 . . . . . . . Methods of inactivation or attenuation
2760/00062 . . . . . . . by genetic engineering
2760/00063 . . . . . . . by chemical treatment
2760/00064 . . . . . . . by serial passage
2760/00071 . . . . . . . Demonstrated in vivo effect
2760/00088 . . . . . . . For redistribution
2760/10011 . Arenaviridae
2760/10021 . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/10022 . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/10023 . Virus like particles [VLP]
2760/10031 . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/10032 . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/10033 . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/10034 . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/10041 . Use of virus, viral particle or viral elements as a vector
2760/10042 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/10043 . . . viral genome or elements thereof as genetic vector
2760/10044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/10045 . . . Special targeting system for viral vectors
2760/10051 . . . Methods of production or purification of viral material
2760/10052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/10061 . . . Methods of inactivation or attenuation
2760/10062 . . . by genetic engineering
2760/10063 . . . by chemical treatment
2760/10064 . . . by serial passage
2760/10071 . . . Demonstrated in vivo effect
2760/10088 . . . For redistribution
2760/10111 . . . Deltavirus, e.g. hepatitis delta virus
2760/10121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/10122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/10123 . . . Virus like particles [VLP]
2760/10131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/10132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/10133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/10134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/10141 . . . Use of virus, viral particle or viral elements as a vector
2760/10142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/10143 . . . viral genome or elements thereof as genetic vector
2760/10144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/10145 . . . Special targeting system for viral vectors
2760/10151 . . . Methods of production or purification of viral material
2760/10152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/10161 . . . Methods of inactivation or attenuation
2760/10162 . . . by genetic engineering
2760/10163 . . . by chemical treatment
2760/10164 . . . by serial passage
2760/10171 . . . Demonstrated in vivo effect
2760/10188 . . . For redistribution
2760/12011 . . . Bunyaviridae
2760/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/12023 . . . Virus like particles [VLP]
2760/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/12041 . . . Use of virus, viral particle or viral elements as a vector
2760/12042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/12043 . . . viral genome or elements thereof as genetic vector
2760/12044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/12045 . . . Special targeting system for viral vectors
2760/12051 . . . Methods of production or purification of viral material
2760/12052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/12061 . . . Methods of inactivation or attenuation
2760/12062 . . . by genetic engineering
2760/12063 . . . by chemical treatment
2760/12064 . . . by serial passage
2760/12071 . . . Demonstrated in vivo effect
2760/12088 . . . For redistribution
2760/12111 . . . Hantavirus, e.g. Hantaan virus
2760/12121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/12122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/12123 . . . Virus like particles [VLP]
2760/12131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/12132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/12133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/12134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/12141 . . . Use of virus, viral particle or viral elements as a vector
2760/12142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/12143 . . . viral genome or elements thereof as genetic vector
2760/12144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/12145 . . . Special targeting system for viral vectors
2760/12151 . . . Methods of production or purification of viral material
2760/12152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/12161 . . . Methods of inactivation or attenuation
2760/12162 . . . by genetic engineering
2760/12163 . . . by chemical treatment
Filoviridae

Marburgvirus, e.g. Lake Victoria Marburgvirus
Ebola virus, e.g. Zaire ebolavirus

Methods of inactivation or attenuation

Virus like particles [VLP]

Virus as such, e.g. new isolates, mutants or their genomic sequences
Virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

For redistribution

Virus genome or elements thereof as genetic vector
Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Virus like particle or viral elements as a vector

Virus like particles [VLP]

Virus as such, e.g. new isolates, mutants or their genomic sequences
Virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

For redistribution

Viral genome or elements thereof as genetic vector
Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Viral protein as therapeutic agent other than vaccine, e.g. as cytolytic agent

Methods of inactivation or attenuation

Virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

For redistribution

Viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Virus like particles [VLP]

Virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

For redistribution

Virus as such, e.g. new isolates, mutants or their genomic sequences
Virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

For redistribution

Virus genome or elements thereof as genetic vector
Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Virus genome or elements thereof as genetic vector
Chimeric viral vector comprising heterologous viral elements for production of another viral vector

For redistribution

Virus as such, e.g. new isolates, mutants or their genomic sequences
Virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

For redistribution

Virus genome or elements thereof as genetic vector
Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Virus like particle or viral elements as a vector

Virus like particle or viral elements as a vector

Virus genome or elements thereof as genetic vector
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/14232 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/14233 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/14234 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/14241 . . . Use of virus, viral particle or viral elements as a vector
2760/14242 . . . Virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/14243 . . . Viral genome or elements thereof as genetic vector
2760/14244 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/14245 . . . Special targeting system for viral vectors
2760/14251 . . . Methods of production or purification of viral material
2760/14252 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/14261 . . . Methods of inactivation or attenuation
2760/14262 . . . by genetic engineering
2760/14263 . . . by chemical treatment
2760/14264 . . . by serial passage
2760/14271 . . . Demonstrated in vivo effect
2760/14288 . . . For redistribution
2760/16011 . . . Orthomyxoviridae
2760/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/16023 . . . Virus like particles [VLP]
2760/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/16041 . . . Use of virus, viral particle or viral elements as a vector
2760/16042 . . . Virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/16043 . . . Viral genome or elements thereof as genetic vector
2760/16044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/16045 . . . Special targeting system for viral vectors
2760/16051 . . . Methods of production or purification of viral material
2760/16052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/16061 . . . Methods of inactivation or attenuation
2760/16062 . . . by genetic engineering
2760/16063 . . . by chemical treatment
2760/16064 . . . by serial passage
2760/16071 . . . Demonstrated in vivo effect
2760/16088 . . . For redistribution
2760/16111 . . . Influenzavirus A, i.e. influenza A virus
2760/16121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/16122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/16123 . . . Virus like particles [VLP]
2760/16131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/16132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/16133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/16134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/16141 . . . Use of virus, viral particle or viral elements as a vector
2760/16142 . . . Virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/16143 . . . Viral genome or elements thereof as genetic vector
2760/16144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/16145 . . . Special targeting system for viral vectors
2760/16151 . . . Methods of production or purification of viral material
2760/16152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/16161 . . . Methods of inactivation or attenuation
2760/16162 . . . by genetic engineering
2760/16163 . . . by chemical treatment
2760/16164 . . . by serial passage
2760/16171 . . . Demonstrated in vivo effect
2760/16188 . . . For redistribution
2760/16211 . . . Influenzavirus B, i.e. influenza B virus
2760/16221 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/16222 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/16223 . . . Virus like particles [VLP]
2760/16231 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/16232 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/16233 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/16234 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/16241 . . . Use of virus, viral particle or viral elements as a vector
2760/16242 . . . Virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/16243 . . . Viral genome or elements thereof as genetic vector
Chimeric viral vector comprising heterologous viral elements for production of another viral vector.

Methods of inactivation or attenuation.

Viral genome or elements thereof as genetic vector.

Special targeting system for viral vectors.

Methods of production or purification of viral material.

For redistribution.

Influenzavirus C, i.e. influenza C virus.

Viruses as such, e.g. new isolates, mutants or their genomic sequences.

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes.

Viruses like particles [VLP].

Uses of virus other than therapeutic or vaccine, e.g. disinfectant.

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent.

Use of virus as therapeutic agent, other than vaccine, e.g. as a vector.

Virus like particles [VLP].

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory.

Special targeting system for viral vectors.

Methods of production or purification of viral material.

For redistribution.

Avulavirus, e.g. Newcastle disease virus.

Viruses as such, e.g. new isolates, mutants or their genomic sequences.

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes.

Virus like particles [VLP].

Uses of virus other than therapeutic or vaccine, e.g. disinfectant.

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent.

Use of virus as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory.

For redistribution.

Paramyxoviridae.

Viruses as such, e.g. new isolates, mutants or their genomic sequences.

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes.

Virus like particles [VLP].

Uses of virus other than therapeutic or vaccine, e.g. disinfectant.

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent.

Use of viral protein as therapeutic agent other than vaccine, e.g. as cytolytic agent.

Use of virus or viral component as vaccine, e.g. encapsulating small organic molecule.

Chimeric viral vector comprising heterologous viral elements for production of another viral vector.

Special targeting system for viral vectors.

Methods of production or purification of viral material.

For redistribution.

Avulavirus, e.g. Newcastle disease virus.

Viruses as such, e.g. new isolates, mutants or their genomic sequences.

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes.

Virus like particles [VLP].

Uses of virus other than therapeutic or vaccine, e.g. disinfectant.

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent.

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory.

Methods of inactivation or attenuation.

Viral genome or elements thereof as genetic vector.

Special targeting system for viral vectors.

Methods of production or purification of viral material.

For redistribution.

Avulavirus, e.g. Newcastle disease virus.

Viruses as such, e.g. new isolates, mutants or their genomic sequences.

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes.

Virus like particles [VLP].

Uses of virus other than therapeutic or vaccine, e.g. disinfectant.

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent.

Use of viral protein as therapeutic agent other than vaccine, e.g. as cytolytic agent.

Use of virus or viral component as vaccine, e.g. encapsulating small organic molecule.

Chimeric viral vector comprising heterologous viral elements for production of another viral vector.

Special targeting system for viral vectors.

Methods of production or purification of viral material.

For redistribution.

Avulavirus, e.g. Newcastle disease virus.
Metapneumovirus, e.g. avian pneumovirus
Henipavirus, e.g. hendra virus
as a vector
Use of virus, viral particle or viral elements as a vector
Use of virus, viral particle or viral elements as a vector
viral genome or elements thereof as genetic vector
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
Methods of production or purification of viral material
relating to complementing cells and packaging systems for producing virus or viral particles
Methods of inactivation or attenuation
by genetic engineering
by chemical treatment
by serial passage
Demonstrated in vivo effect
For redistribution
Metapneumovirus, e.g. avian pneumovirus
Viruses as such, e.g. new isolates, mutants or their genomic sequences
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Viruses as such, e.g. new isolates, mutants or their genomic sequences
Viruses as such, e.g. new isolates, mutants or their genomic sequences
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Viruses as such, e.g. new isolates, mutants or their genomic sequences
Viruses as such, e.g. new isolates, mutants or their genomic sequences
Viruses as such, e.g. new isolates, mutants or their genomic sequences
Viruses as such, e.g. new isolates, mutants or their genomic sequences
Viruses as such, e.g. new isolates, mutants or their genomic sequences
Viruses as such, e.g. new isolates, mutants or their genomic sequences
Rhabdoviridae
Lyssavirus, e.g. rabies virus

For redistribution
Demonstrated in vivo effect

Methods of inactivation or attenuation

Viral genome or elements thereof
Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Virus like particles [VLP]

Vesiculovirus, e.g. vesicular stomatitis Indiana virus

Virus as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Vesiculovirus, e.g. vesicular stomatitis Indiana virus

Virus as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
ssRNA Viruses positive-sense (not used)

- Methods of inactivation or attenuation
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Use of virus, viral particle or viral elements as a vector
- Virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- Viral genome or elements thereof as genetic vector
- Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Special targeting system for viral vectors
- Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles
- For redistribution

Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Special targeting system for viral vectors
- Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles
- For redistribution

Virus like particles [VLP]
- by genetic engineering
- by chemical treatment
- by serial passage
- Demonstrated in vivo effect
- For redistribution

Astroviridae
- Virus like particles [VLP]
- proteins or genes
- structural or functional aspects of known viral proteins or genes
- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Live-attenuated or inactivated virus, VLP, viral protein
- virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- viral genome or elements thereof as genetic vector
- Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Methods of inactivation or attenuation
- by genetic engineering
- by chemical treatment
- by serial passage
- Demonstrated in vivo effect
- For redistribution

Bromoviridae
- Virus like particles [VLP]
- proteins or genes
- structural or functional aspects of known viral proteins or genes
- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Live-attenuated or inactivated virus, VLP, viral protein
- virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- viral genome or elements thereof as genetic vector
- Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Methods of inactivation or attenuation
- by genetic engineering
- by chemical treatment
- by serial passage
- Demonstrated in vivo effect
- For redistribution

For redistribution

Demonstrated in vivo effect
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

Relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Caliciviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

by serial passage

Demonstrated in vivo effect

For redistribution

Coronaviridae

Comoviridae

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Use of virus other than therapeutic or vaccine, e.g. disinfectant

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

by serial passage

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

Relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Coronaviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Use of virus other than therapeutic or vaccine, e.g. disinfectant

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

by serial passage

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

Relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Coronaviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Use of virus other than therapeutic or vaccine, e.g. disinfectant
Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of inactivation or attenuation

Use of virus, viral particle or viral elements as a vector

Virus like particles [VLP]

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses as such, e.g. new isolates, mutants or their genomic sequences

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Methods of production or purification of viral material

related to complementing cells and packaging systems for producing virus or viral particles

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Virus like particles [VLP]

Viral genome or elements thereof as genetic vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Methods of inactivation or attenuation

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

For redistribution

Use of virus, viral particle or viral elements as a vector

Virus like particles [VLP]

Viral genome or elements thereof as genetic vector

Special targeting system for viral vectors

Methods of production or purification of viral material

related to complementing cells and packaging systems for producing virus or viral particles

Viruses as such, e.g. new isolates, mutants or their genomic sequences

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Methods of inactivation or attenuation

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

For redistribution

Use of virus, viral particle or viral elements as a vector

Virus like particles [VLP]

Viral genome or elements thereof as genetic vector

Special targeting system for viral vectors

Methods of production or purification of viral material

related to complementing cells and packaging systems for producing virus or viral particles

Viruses as such, e.g. new isolates, mutants or their genomic sequences

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Methods of inactivation or attenuation

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

For redistribution

Use of virus, viral particle or viral elements as a vector

Virus like particles [VLP]

Viral genome or elements thereof as genetic vector

Special targeting system for viral vectors

Methods of production or purification of viral material

related to complementing cells and packaging systems for producing virus or viral particles

Viruses as such, e.g. new isolates, mutants or their genomic sequences

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Methods of inactivation or attenuation

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

For redistribution

Use of virus, viral particle or viral elements as a vector

Virus like particles [VLP]

Viral genome or elements thereof as genetic vector

Special targeting system for viral vectors

Methods of production or purification of viral material

related to complementing cells and packaging systems for producing virus or viral particles

Viruses as such, e.g. new isolates, mutants or their genomic sequences

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Methods of inactivation or attenuation

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

For redistribution

Use of virus, viral particle or viral elements as a vector

Virus like particles [VLP]

Viral genome or elements thereof as genetic vector

Special targeting system for viral vectors

Methods of production or purification of viral material

related to complementing cells and packaging systems for producing virus or viral particles
Pestivirus, e.g. bovine viral diarrhea virus as a vector

Use of virus, viral particle or viral elements e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Methods of inactivation or attenuation

by serial passage

by chemical treatment

by genetic engineering

heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

For redistribution

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Flexiviridae

Virus as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Hepevirus, e.g. hepatitis E virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

For redistribution

Nodaviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

For redistribution

Picornaviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

For redistribution

viral genome or elements thereof as genetic vector

Virus like particles [VLP]
2770/32044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32045 . . . . Special targeting system for viral vectors
2770/32051 . . . . Methods of production or purification of viral material
2770/32052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/32061 . . . . Methods of inactivation or attenuation
2770/32062 . . . . by genetic engineering
2770/32063 . . . . by chemical treatment
2770/32064 . . . . by serial passage
2770/32071 . . . . Demonstrated in vivo effect
2770/32088 . . . . For redistribution
2770/32111 . . . . Aphthovirus, e.g. footandmouth disease virus
2770/32121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32123 . . . . Virus like particles [VLP]
2770/32131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/32133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32141 . . . . Use of virus, viral particle or viral elements as a vector
2770/32142 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32143 . . . . viral genome or elements thereof as genetic vector
2770/32144 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32145 . . . . Special targeting system for viral vectors
2770/32151 . . . . Methods of production or purification of viral material
2770/32152 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/32161 . . . . Methods of inactivation or attenuation
2770/32162 . . . . by genetic engineering
2770/32163 . . . . by chemical treatment
2770/32164 . . . . by serial passage
2770/32171 . . . . Demonstrated in vivo effect
2770/32188 . . . . For redistribution
2770/32211 . . . . Cardiovirus, e.g. encephalomyocarditis virus
2770/32221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32223 . . . . Virus like particles [VLP]
2770/32231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/32233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32241 . . . . Use of virus, viral particle or viral elements as a vector
2770/32242 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32243 . . . . viral genome or elements thereof as genetic vector
2770/32244 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32245 . . . . Special targeting system for viral vectors
2770/32251 . . . . Methods of production or purification of viral material
2770/32252 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/32261 . . . . Methods of inactivation or attenuation
2770/32262 . . . . by genetic engineering
2770/32263 . . . . by chemical treatment
2770/32264 . . . . by serial passage
2770/32271 . . . . Demonstrated in vivo effect
2770/32288 . . . . For redistribution
2770/32311 . . . . Enterovirus
2770/32321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32323 . . . . Virus like particles [VLP]
2770/32331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/32333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32341 . . . . Use of virus, viral particle or viral elements as a vector
2770/32342 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32343 . . . . viral genome or elements thereof as genetic vector
2770/32344 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32345 . . . . Special targeting system for viral vectors
2770/32351 . . . . Methods of production or purification of viral material
2770/32352 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/32361 . . . . Methods of inactivation or attenuation
2770/32362 . . . . by genetic engineering
2770/32363 . . . . by chemical treatment
2770/32364 . . . . by serial passage
2770/32371 . . . . Demonstrated in vivo effect
CPC - 2019.05

2770/32388 . . . . . . . . . . . . For redistribution
2770/32411 . . . . . . . . . . . . Hepatovirus, i.e. hepatitis A virus
2770/32421 . . . . . . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32422 . . . . . . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32423 . . . . . . . . . . . . Virus like particles [VLP]
2770/32431 . . . . . . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32432 . . . . . . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/32433 . . . . . . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32434 . . . . . . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32441 . . . . . . . . . . . . Use of virus, viral particle or viral elements as a vector
2770/32442 . . . . . . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32443 . . . . . . . . . . . . viral genome or elements thereof as genetic vector
2770/32444 . . . . . . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32445 . . . . . . . . . . . . Special targeting system for viral vectors
2770/32451 . . . . . . . . . . . . Methods of production or purification of viral material
2770/32452 . . . . . . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/32461 . . . . . . . . . . . . Methods of inactivation or attenuation
2770/32462 . . . . . . . . . . . . by genetic engineering
2770/32463 . . . . . . . . . . . . by chemical treatment
2770/32464 . . . . . . . . . . . . by serial passage
2770/32471 . . . . . . . . . . . . Demonstrated in vivo effect
2770/32488 . . . . . . . . . . . . For redistribution
2770/32511 . . . . . . . . . . . . Parechovirus, e.g. human parechovirus
2770/32521 . . . . . . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32522 . . . . . . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32523 . . . . . . . . . . . . Virus like particles [VLP]
2770/32531 . . . . . . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32532 . . . . . . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/32533 . . . . . . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32534 . . . . . . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32541 . . . . . . . . . . . . Use of virus, viral particle or viral elements as a vector
2770/32542 . . . . . . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32543 . . . . . . . . . . . . viral genome or elements thereof as genetic vector
2770/32544 . . . . . . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32545 . . . . . . . . . . . . Special targeting system for viral vectors
2770/32551 . . . . . . . . . . . . Methods of production or purification of viral material
2770/32552 . . . . . . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/32561 . . . . . . . . . . . . Methods of inactivation or attenuation
2770/32562 . . . . . . . . . . . . by genetic engineering
2770/32563 . . . . . . . . . . . . by chemical treatment
2770/32564 . . . . . . . . . . . . by serial passage
2770/32571 . . . . . . . . . . . . Demonstrated in vivo effect
2770/32588 . . . . . . . . . . . . For redistribution
2770/32611 . . . . . . . . . . . . Poliovirus
2770/32621 . . . . . . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32622 . . . . . . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32623 . . . . . . . . . . . . Virus like particles [VLP]
2770/32631 . . . . . . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32632 . . . . . . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/32633 . . . . . . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32634 . . . . . . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32641 . . . . . . . . . . . . Use of virus, viral particle or viral elements as a vector
2770/32642 . . . . . . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32643 . . . . . . . . . . . . viral genome or elements thereof as genetic vector
2770/32644 . . . . . . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32645 . . . . . . . . . . . . Special targeting system for viral vectors
2770/32651 . . . . . . . . . . . . Methods of production or purification of viral material
2770/32652 . . . . . . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/32661 . . . . . . . . . . . . Methods of inactivation or attenuation
2770/32662 . . . . . . . . . . . . by genetic engineering
2770/32663 . . . . . . . . . . . . by chemical treatment
2770/32664 . . . . . . . . . . . . by serial passage
2770/32671 . . . . . . . . . . . . Demonstrated in vivo effect
2770/32688 . . . . . . . . . . . . For redistribution
2770/32711 . . . . . . . . . . . . Rhinovirus
2770/32721 . . . . . . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32722 . . . . . . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32723 . . . . . . . . . . . . Virus like particles [VLP]
2770/32731 . . . . . . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32732 . . . . . . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

CPC - 2019.05
45
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Potyviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

Viruses like particles [VLP]

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

For redistribution

Potyviridae

WEE, Semliki

For redistribution
Chimeric viral vector comprising heterologous viral elements for production of another viral vector.

Methods of inactivation or attenuation by serial passage.

Viruses as such, e.g. new isolates, mutants or their genomic sequences.

Viruses like particles [VLP].

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein.

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory.

Chimeric viral vector comprising heterologous viral elements for production of another viral vector.

Special targeting system for viral vectors.

Methods of production or purification of viral material.

relating to complementing cells and packaging systems for producing virus or viral particles.

by genetic engineering.

by chemical treatment.

by serial passage.

Demonstrated in vivo effect.

For redistribution.

Rubivirus, e.g. rubella virus.

Virus like particles [VLP].

proteins or genes.

structural or functional aspects of known viral proteins or genes.

Viruses as such, e.g. new isolates, mutants or their genomic sequences.

VLP.

protein.

viral genome or elements thereof as genetic vector.

Chimeric viral vector comprising heterologous viral elements for production of another viral vector.

Methods of production or purification of viral material.

relating to complementing cells and packaging systems for producing virus or viral particles.

by serial passage.

Special targeting system for viral vectors.

Methods of production or purification of viral material.

relating to complementing cells and packaging systems for producing virus or viral particles.

by genetic engineering.

by chemical treatment.

by serial passage.

Demonstrated in vivo effect.

For redistribution.

Virus like particles [VLP].

Uses of virus other than therapeutic or vaccine, e.g. disinfectant.

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory.

Methods of inactivation or attenuation by chemical treatment.

Virus like particles [VLP].

Uses of virus other than therapeutic or vaccine, e.g. disinfectant.

Use of virus as therapeutic agent, other than vaccine, e.g. cytolytic agent.

by serial passage.

Demonstrated in vivo effect.

For redistribution.

Viruses as such, e.g. new isolates, mutants or their genomic sequences.

VLP.

protein.

viral genome or elements thereof as genetic vector.

Chimeric viral vector comprising heterologous viral elements for production of another viral vector.

Special targeting system for viral vectors.

Methods of production or purification of viral material.

relating to complementing cells and packaging systems for producing virus or viral particles.

by genetic engineering.

by chemical treatment.

by serial passage.

Demonstrated in vivo effect.

For redistribution.

Rubivirus, e.g. rubella virus.

Virus like particles [VLP].

proteins or genes.

structural or functional aspects of known viral proteins or genes.

Viruses as such, e.g. new isolates, mutants or their genomic sequences.

VLP.

protein.

viral genome or elements thereof as genetic vector.

Chimeric viral vector comprising heterologous viral elements for production of another viral vector.

Special targeting system for viral vectors.

Methods of production or purification of viral material.

relating to complementing cells and packaging systems for producing virus or viral particles.

by genetic engineering.

by chemical treatment.

by serial passage.

Demonstrated in vivo effect.

For redistribution.

Rubivirus, e.g. rubella virus.

Virus like particles [VLP].

proteins or genes.

structural or functional aspects of known viral proteins or genes.

Viruses as such, e.g. new isolates, mutants or their genomic sequences.

VLP.

protein.

viral genome or elements thereof as genetic vector.

Chimeric viral vector comprising heterologous viral elements for production of another viral vector.

Special targeting system for viral vectors.
C12N

2780/00 Naked RNA Viruses (not used)
2780/00014 Naked RNA Viruses
2780/00021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
2780/00022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2780/00023 Virus like particles [VLP]
2780/00031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2780/00032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2780/00033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2780/00034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2780/00041 Use of virus, viral particle or viral elements as a vector
2780/00042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2780/00043 viral genome or elements thereof as genetic vector
2780/00044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2780/00045 Special targeting system for viral vectors
2780/00051 Methods of production or purification of viral material
2780/00052 relating to complementing cells and packaging systems for producing virus or viral particles
2780/00061 Methods of inactivation or attenuation
2780/00062 by genetic engineering
2780/00063 by chemical treatment
2780/00064 by serial passage
2780/00071 Demonstrated in vivo effect
2780/00088 For redistribution
2780/10011 Narnaviridae
2780/10021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
2780/10022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2780/10023 Virus like particles [VLP]
2780/10031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2780/10032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2780/10033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2780/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2780/10041 Use of virus, viral particle or viral elements as a vector
2780/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2780/10043 viral genome or elements thereof as genetic vector
2780/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2780/10045 Special targeting system for viral vectors
2780/10051 Methods of production or purification of viral material
2780/10052 relating to complementing cells and packaging systems for producing virus or viral particles
2780/10061 Methods of inactivation or attenuation
2780/10062 by genetic engineering
2780/10063 by chemical treatment
2780/10064 by serial passage
2780/10071 Demonstrated in vivo effect
2780/10088 For redistribution
2790/00011 Viroids and subviral agents
2790/00014 Viruses as such, e.g. new isolates, mutants or their genomic sequences
2790/00021 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2790/00023 Virus like particles [VLP]
2790/00031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2790/00032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2790/00033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2790/00034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2790/00041 Use of virus, viral particle or viral elements as a vector
2790/00042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2790/00043 viral genome or elements thereof as genetic vector
2790/00044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2790/00045 Special targeting system for viral vectors
2790/00051 Methods of production or purification of viral material
2790/00052 relating to complementing cells and packaging systems for producing virus or viral particles
2790/00061 Methods of inactivation or attenuation
2790/00062 by genetic engineering
2790/00063 by chemical treatment
2790/00064 by serial passage
2790/00071 Demonstrated in vivo effect
2790/00088 For redistribution
2790/10011 Prions
2790/10021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
2790/10022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2790/10023 Virus like particles [VLP]
2790/10031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2790/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2790/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2790/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2790/10041 . . . Use of virus, viral particle or viral elements as a vector
2790/10042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2790/10043 . . . viral genome or elements thereof as genetic vector
2790/10044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2790/10045 . . . Special targeting system for viral vectors
2790/10051 . . . Methods of production or purification of viral material
2790/10052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2790/10061 . . . Methods of inactivation or attenuation
2790/10062 . . . by genetic engineering
2790/10063 . . . by chemical treatment
2790/10064 . . . by serial passage
2790/10071 . . . Demonstrated in vivo effect
2790/10088 . . . For redistribution
2790/12011 . . . Satellite viruses
2790/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2790/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2790/12023 . . . Virus like particles [VLP]
2790/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2790/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2790/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2790/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2790/12041 . . . Use of virus, viral particle or viral elements as a vector
2790/12042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2790/12043 . . . viral genome or elements thereof as genetic vector
2790/12044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2790/12045 . . . Special targeting system for viral vectors
2790/12051 . . . Methods of production or purification of viral material
2790/12052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2790/12061 . . . Methods of inactivation or attenuation
2790/12062 . . . by genetic engineering
2790/12063 . . . by chemical treatment
2790/12064 . . . by serial passage
2790/12071 . . . Demonstrated in vivo effect
2790/12088 . . . For redistribution
2790/14011 . . . Viroids
2790/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2790/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2790/14023 . . . Virus like particles [VLP]
2790/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2790/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2790/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2790/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2790/14041 . . . Use of virus, viral particle or viral elements as a vector
2790/14042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2790/14043 . . . viral genome or elements thereof as genetic vector
2790/14044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2790/14045 . . . Special targeting system for viral vectors
2790/14051 . . . Methods of production or purification of viral material
2790/14052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2790/14061 . . . Methods of inactivation or attenuation
2790/14062 . . . by genetic engineering
2790/14063 . . . by chemical treatment
2790/14064 . . . by serial passage
2790/14071 . . . Demonstrated in vivo effect
2790/14088 . . . For redistribution
2792/0000 . Archaeabacteria viruses (not used)
2792/00011 . . . Archaeabacteria viruses
2792/00021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2792/00022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2792/00023 . . . Virus like particles [VLP]
2792/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2792/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2792/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2792/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2792/00041 . . . Use of virus, viral particle or viral elements as a vector
2792/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N

- Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Use of virus, viral particle or viral elements as a vector
- virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- Special targeting system for viral vectors
- Bacteriophages (not used)
- Bacteriophages
- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Virus like particles [VLP]
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- Use of virus, viral particle or viral elements as a vector
- virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Special targeting system for viral vectors
- Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles
- Methods of inactivation or attenuation
- by genetic engineering
- by chemical treatment
- by serial passage
- Demonstrated in vivo effect
- For redistribution
- Fuselloviridae
- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Virus like particles [VLP]
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- Use of virus, viral particle or viral elements as a vector
- virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Special targeting system for viral vectors
- Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles
- Methods of inactivation or attenuation
- by genetic engineering
- by chemical treatment
- by serial passage
- Demonstrated in vivo effect
- For redistribution
- Guttaviridae
- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Virus like particles [VLP]
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
dsDNA Bacteriophages

Myoviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

For redistribution

Determined in vivo effect

Methods of production or purification of viral material

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Determined in vivo effect

For redistribution

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

by serial passage

Special targeting system for viral vectors

heterologous viral elements for production of another viral vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Viral genome or elements thereof as genetic vector

Viral genome or elements thereof as genetic vector

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Determined in vivo effect

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Viral genome or elements thereof as genetic vector

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Viral genome or elements thereof as genetic vector

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

For redistribution
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

dsRNA Bacteriophages

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Inoviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

viruses or viral particle as vehicle, e.g. encapsulating small organic molecule

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

For redistribution

Inoviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of inactivation or attenuation by serial passage

Special targeting system for viral vectors relating to complementing cells and packaging systems for producing virus or viral particles

Microviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP] Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] by genetic engineering

Use of virus, viral particle or viral elements as a vector

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Viral genome or elements thereof as genetic vector

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Methods of inactivation or attenuation by genetic engineering

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Virus like particles [VLP] by chemical treatment

Use of virus, viral particle or viral elements as a vector

Virus like particles [VLP] by serial passage

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] by genetic engineering

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] by chemical treatment

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] by serial passage

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] Demonstrated in vivo effect

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages negative-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP] For redistribution

ssRNA Bacteriophages positive-sense

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Methods of production or purification of viral material

Virus like particles [VLP]
2795/18088 . . . . For redistribution
2795/18111 . . . . Leviriviridae
2795/18121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/18122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/18123 . . . . Virus like particles [VLP]
2795/18131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/18132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/18133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/18134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/18141 . . . . Use of virus, viral particle or viral elements as a vector
2795/18142 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/18143 . . . . viral genome or elements thereof as genetic vector
2795/18144 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/18145 . . . . Special targeting system for viral vectors
2795/18151 . . . . Methods of production or purification of viral material
2795/18152 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2795/18161 . . . . Methods of inactivation or attenuation
2795/18162 . . . . by genetic engineering
2795/18163 . . . . by chemical treatment
2795/18164 . . . . by serial passage
2795/18171 . . . . Demonstrated in vivo effect
2795/18188 . . . . For redistribution

2799/00 Uses of viruses

**WARNING**

From March 15, 2012 codes in the range C12N 2799/00 - C12N 2799/06 are no longer used for the classification of new documents. The documents in this range are being reclassified to the corresponding codes in C12N 2710/00-2795/00

2799/02 . . . . as vector
2799/021 . . . . for the expression of a heterologous nucleic acid
2799/022 . . . . where the vector is derived from an adenovirus
2799/023 . . . . where the vector is derived from a poxvirus
2799/025 . . . . where the vector is derived from a parvovirus
2799/026 . . . . where the vector is derived from a baculovirus
2799/027 . . . . where the vector is derived from a retrovirus
2799/028 . . . . where the vector is derived from a herpesvirus
2799/04 . . . . in vivo
2799/06 . . . . in vitro

**2800/00** Nucleic acids vectors

2800/10 . . . . Plasmid DNA
2800/101 . . . . for bacteria
2800/102 . . . . for yeast

2800/103 . . . . for invertebrates
2800/105 . . . . for insects
2800/106 . . . . for vertebrates
2800/107 . . . . for mammalian
2800/108 . . . . episomal vectors
2800/20 . . . . Pseudochromosomes, minichromosomes
2800/202 . . . . of bacteriophage origin
2800/204 . . . . of bacterial origin, e.g. BAC
2800/206 . . . . of yeast origin, e.g. YAC, 2u
2800/208 . . . . of mammalian origin, e.g. minichromosome
2800/22 . . . . Vectors comprising a coding region that has been codon optimised for expression in a respective host
2800/24 . . . . Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
2800/30 . . . . Vectors comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
2800/40 . . . . Systems of functionally co-operating vectors
2800/45 . . . . Vectors containing traps for, e.g. exons, promoters
2800/70 . . . . Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
2800/80 . . . . Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
2800/90 . . . . Vectors containing a transposable element
2800/95 . . . . Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers

**2810/00** Vectors comprising a targeting moiety

2810/10 . . . . Vectors comprising a non-peptidic targeting moiety
2810/40 . . . . Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
2810/405 . . . . Vectors comprising RGD peptide
2810/50 . . . . Vectors comprising as targeting moiety peptide derived from defined protein
2810/55 . . . . from bacteria
2810/60 . . . . from viruses
2810/6009 . . . . dsDNA viruses
2810/6018 . . . . Adenoviridae
2810/6027 . . . . ssDNA viruses
2810/6036 . . . . DNA rev transcr viruses
2810/6045 . . . . RNA rev transcr viruses
2810/6054 . . . . Retroviridae
2810/6063 . . . . ds RNA viruses
2810/6072 . . . . negative strand RNA viruses
2810/6081 . . . . rhabdoviridae, e.g. VSV
2810/609 . . . . positive strand RNA viruses
2810/65 . . . . from plants
2810/70 . . . . from fungi
2810/75 . . . . from invertebrates
2810/80 . . . . from vertebrates
2810/85 . . . . mammalian
2810/851 . . . . from growth factors; from growth regulators
2810/852 . . . . from cytokines; from lymphokines; from interferons
2810/853 . . . . from tumor necrosis factor, TNF
2810/854 . . . . from hormones
2810/855 . . . . from receptors; from cell surface antigens; from cell surface determinants
2810/856 . . . . from integrins
2810/857 . . . . from blood coagulation or fibrinolysis factors
2810/858 . . . . from apolipoproteins
2810/859 . . . . from immunoglobulins
2820/00 Vectors comprising a special origin of replication system

2820/002 inducible or controllable
2820/005 cell-cycle regulated
2820/007 tissue or cell-specific
2820/10 multiple origins of replication
2820/55 from bacteria
2820/60 from viruses
2820/65 from plants
2820/70 from fungi
2820/702 yeast
2820/704 S. cerevisiae
2820/706 S. pombe
2820/708 C. albicans
2820/75 from invertebrates
2820/80 from vertebrates
2820/85 mammalian
2820/90 avian

2830/00 Vector systems having a special element relevant for transcription

2830/001 controllable enhancer/promoter combination
2830/002 inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
2830/003 tet inducible
2830/005 repressible enhancer/promoter combination, e.g. KRAB
2830/006 tet repressible
2830/007 cell cycle specific enhancer/promoter combination
2830/008 cell type or tissue specific enhancer/promoter combination
2830/15 chimeric enhancer/promoter combination
2830/20 transcription of more than one cistron
2830/205 bidirectional
2830/30 being an enhancer not forming part of the promoter region
2830/32 being a silencer not forming part of the promoter region
2830/34 being a transcription initiation element
2830/36 being a transcription termination element
2830/38 being a stuffer
2830/40 being an insulator
2830/42 being an intron or intervening sequence for splicing and/or stability of RNA
2830/46 elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
2830/48 regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
2830/50 regulating RNA stability, not being an intron, e.g. poly A signal
2830/52 encoding ribozyme for self-inactivation
2830/55 from bacteria
2830/60 from viruses
2830/65 from plants
2830/70 from fungi
2830/702 yeast
2830/704 S. cerevisiae
2830/706 S. pombe
2830/708 C. albicans
2830/75 from invertebrates

2830/80 from vertebrates
2830/85 mammalian
2830/90 avian

2840/00 Vectors comprising a special translation-regulating system

2840/002 controllable or inducible
2840/005 cell cycle specific
2840/007 cell or tissue specific
2840/10 regulates levels of translation
2840/102 inhibiting translation
2840/105 enhancing translation
2840/107 inhibiting translational read-through
2840/20 translation of more than one cistron
2840/203 having an IRES
2840/206 having multiple IRES
2840/44 being a specific part of the splice mechanism, e.g. donor, acceptor
2840/445 for trans-splicing, e.g. polypyrimidine tract, branch point splicing
2840/50 utilisation of non-ATG initiation codon

NOTE
This group covers artificial modification only, i.e. naturally occurring use of non-ATG start codon is not classified here

2840/55 from bacteria
2840/60 from viruses
2840/65 from plants
2840/70 from fungi
2840/702 yeast
2840/704 S. cerevisiae
2840/706 S. pombe
2840/708 C. albicans
2840/75 from invertebrates
2840/80 from vertebrates
2840/85 mammalian
2840/90 avian

2999/00 Further aspects of viruses or vectors not covered by the C12N 2700/00 or C12N 2800/00 series

NOTES
1. This group is for classification of patent and non-patent literature documents.
2. When classifying non-patent literature in this group, classification must also be given for the relevant CPC groups, to define the technical area to which they relate.

2999/002 Adverse teaching
2999/005 Biological teaching, e.g. a link between protein and disease, new virus causing pandemic
2999/007 Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals